Amine-containing transfection reagent, preparation method and transfection complex

By developing an amine-containing transfection reagent and its transfection complex, the toxicity problem of nucleic acid delivery in the prior art has been solved, low toxicity and high efficiency delivery have been achieved, and the maximum tolerated dose has been significantly improved.

CN114761376BActive Publication Date: 2024-11-08SUZHOU RIBO LIFE SCIENCE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980102539.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-12-13
Publication Date
2024-11-08
Estimated Expiration
2039-12-13

AI Technical Summary

Technical Problem

The existing amine-containing liposomes have toxicity problems when used for nucleic acid delivery, which is difficult to achieve while improving delivery activity and reducing toxicity.

Method used

An amine-containing transfection agent has been developed to increase biological activity and reduce toxicity by forming transfection complexes with pharmaceutically acceptable salts, utilizing specific compound structures and preparation methods, and to improve biological activity and reduce toxicity. Deliver nucleic acid drugs.

Benefits of technology

It has achieved the improvement of the delivery efficiency and biological activity of nucleic acid drugs under low toxicity, showing excellent target gene inhibition effect and low liver acute toxicity in vivo, and significantly improved the maximum tolerated dose.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114761376B_ABST
    Figure CN114761376B_ABST
Patent Text Reader

Abstract

The present disclosure relates to an amine-containing transfection reagent and a preparation method thereof, and a transfection complex containing the amine-containing transfection reagent. The amine-containing transfection reagent is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and the transfection complex containing the amine-containing transfection reagent has better biological activity and unexpectedly low toxicity#imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the field of biomedicine, and in particular to an amine-containing transfection reagent that can be used to deliver a bioactive agent, a method for preparing the amine-containing transfection reagent, and a transfection complex comprising the amine-containing transfection reagent. Background Art

[0002] Liposome is an artificial membrane with a double-layer structure containing lipids, generally comprising components such as phospholipids and cholesterol, and forming nano lipid particles in a solution. Liposome can be used to encapsulate and deliver drugs, and deliver drugs into the interior of cells. Liposome can be generally used to deliver small molecule drugs, and there are currently multiple liposome small molecule drugs on the market. In addition, liposome can also be used to encapsulate nucleic acids, transfect nucleic acids into cells, or deliver them to target tissues and enter cells. Amine-containing lipid compounds (i.e., transfection reagents) are generally used in the art to deliver nucleic acid molecules, for example, Chinese patent CN 103380113B describes a variety of amine-containing lipid compounds. The amine groups in these lipid compounds have a strong electrostatic binding effect with DNA or RNA, and can thus be used for the delivery of nucleic acid molecules. However, this amine-containing lipid compound sometimes brings certain toxicity. Therefore, how to reduce toxicity while improving the activity of liposome-delivered nucleic acid drugs is still a problem that needs to be solved in this area. Summary of the invention

[0003] The present disclosure provides an amine-containing transfection reagent. The transfection reagent and a transfection complex comprising the transfection reagent have better biological activity and lower toxicity, and are suitable for in vivo delivery of bioactive agents, especially nucleic acid drugs.

[0004] In some aspects, the present disclosure provides an amine-containing transfection reagent, which is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:

[0005]

[0006] in,

[0007] Y1 is selected from C2-C10 alkylene or C2-C10 alkylene having a substituent;

[0008] Each Y2 is the same or different and is independently selected from a C2-C6 alkylene group or a C2-C6 alkylene group having a substituent;

[0009] Each R1 is the same or different and is independently selected from H or a group represented by formula (Ii); each R2 is independently a group represented by formula (I-ii),

[0010]

[0011] Among them, each Ra and each R b Each independently selected from C6-C20 straight chain alkyl, each R c Each is independently selected from one of the non-amine hydrophilic groups,

[0012] Indicates the site to which a group is covalently attached.

[0013] In some aspects, the present disclosure also provides a method for preparing an amine-containing transfection reagent, wherein the amine-containing transfection reagent is a compound of formula (I) or a pharmaceutically acceptable salt thereof, the method comprising: contacting a compound of formula (301) with a compound of formula (701) in an organic solvent in the presence of a coupling reagent and under coupling reaction conditions, and under conditions sufficient to generate the compound of formula (I), and isolating the compound of formula (I);

[0014]

[0015] In formula (301) and formula (701), the groups Y1, Y2, R a The definition and value range of R2 are as mentioned above. 701 For the leaving group.

[0016] In some aspects, the present disclosure also provides a transfection complex, wherein the transfection complex contains a key lipid, and the key lipid is the above-mentioned amine-containing transfection reagent provided by the present disclosure.

[0017] In some aspects, the present disclosure also provides use of the transfection complex of the present disclosure in preparing a medicament for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in a cell.

[0018] In some aspects, the present disclosure also provides a method for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene, the method comprising administering the transfection complex of the present disclosure to a subject suffering from the pathological condition or disease.

[0019] In some aspects, the present disclosure also provides a method for inhibiting the expression of a specific gene in a cell, the method comprising contacting the transfection complex of the present disclosure with the cell.

[0020] In some aspects, the present disclosure also provides a kit, which comprises the transfection complex provided by the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1The graph shows the inhibition rate of ApoB mRNA expression level in liver tissue of BALB / c mice at doses of 1 mg / kg and 0.5 mg / kg for the transfection complex prepared with the disclosed compound as shown in Example 3 and the control transfection complex.

[0022] Figure 2 The graph shows the inhibition rate of ApoB mRNA expression level in liver tissue of BALB / c mice at a dose of 0.1 mg / kg for the transfection complex prepared with the disclosed compound as shown in Example 3 and the control transfection complex.

[0023] Figure 3 The effect of the transfection complex prepared with the disclosed compound and the comparative transfection complex as shown in Example 3 on the total cholesterol (CHO) concentration in serum of BALB / c mice is shown.

[0024] Figure 4 The effect of the transfection complex prepared with the disclosed compound and the comparative transfection complex as shown in Example 3 on the triglyceride (TG) concentration in serum of BALB / c mice is shown. DETAILED DESCRIPTION

[0025] The specific embodiments of the present disclosure are described in detail below. The features and advantages of the present disclosure will be better understood through the following specific embodiments. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present disclosure and are not intended to limit the present disclosure.

[0026] definition

[0027] As used in the specification and the appended claims, unless specifically stated to the contrary, the terms of the present disclosure have the following meanings:

[0028] As used in this disclosure, a hyphen ("-") that is not between two letters or symbols is used to indicate the position of the point of attachment of a substituent. For example: -C1-C 10 Alkyl-NH2 through C1-C 10 Alkyl group connected.

[0029] As used in the present disclosure, "alkoxy" refers to an alkyl group of a specified number of carbon atoms connected by an oxygen bridge, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy. Alkoxy groups typically have 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms connected by oxygen bridges.

[0030] The term "halogen" refers to fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.

[0031] The term "subject", as used in the present disclosure, refers to any animal, such as a mammal or marsupial. Subjects of the present disclosure include, but are not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cattle, sheep, rats, and poultry of any kind. In some embodiments, a subject refers to a human patient suffering from a specific disease.

[0032] Amine-containing transfection reagents

[0033] In one aspect, the present disclosure provides an amine-containing transfection reagent for delivering a bioactive agent, wherein the amine-containing transfection reagent forms a transfection complex (usually in the form of liposomes) with the bioactive agent as a pharmaceutically active ingredient to deliver the bioactive agent into cells. Wherein, "bioactive agent" includes, but is not limited to, one or more of drug molecules, pharmaceutical compositions, drug complexes, and drug precursors that can be delivered by the transfection complex of the present disclosure and have therapeutic and / or preventive activity, or any one or more of them. Pharmaceutically acceptable salts. In some embodiments, the bioactive agent includes a small molecule drug, a functional oligonucleotide or a drug protein, or their drug precursors or pharmaceutically acceptable salts, particularly those described below in the present disclosure.

[0034] In some embodiments, the present disclosure provides an amine-containing transfection reagent, which is a compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof:

[0035]

[0036] in,

[0037] Y1 is selected from C2-C10 alkylene or C2-C10 alkylene having a substituent;

[0038] Each Y2 is the same or different and is independently selected from a C2-C6 alkylene group or a C2-C6 alkylene group having a substituent;

[0039] Each R1 is the same or different and is independently selected from H or a group represented by formula (Ii); each R2 is independently a group represented by formula (I-ii),

[0040]

[0041] Among them, each R a and each R b Each independently selected from C6-C20 straight chain alkyl, each R c Each is independently selected from one of the non-amine hydrophilic groups,

[0042] Indicates the site to which a group is covalently attached.

[0043] In some embodiments of the present disclosure, Y1 is a C2-C10 straight chain alkylene. In some embodiments, Y1 is a C3-C5 straight chain alkylene. In some embodiments, Y1 is a butylene. The term "alkylene" is a straight or branched divalent saturated hydrocarbon group consisting of carbon atoms and hydrogen atoms, located between two other chemical groups and used to connect the two other chemical groups.

[0044] In some embodiments, Y2 is a C2-C6 alkylene group having a hydroxyl substituent. In some embodiments, each Y2 is independently a C2-C3 alkylene group having a hydroxyl substituent. In some embodiments, each Y2 is a 2-hydroxypropylene group.

[0045] According to the amine-containing transfection reagent provided by the present disclosure, each R2 is independently a group shown in (I-ii), wherein each R b Each independently selected from C6-C20 straight chain alkyl, each R c Each is independently selected from one of the non-amine hydrophilic groups. c When selected from non-amine hydrophilic groups, and in one embodiment selected from hydroxyl groups, the amine-containing transfection reagent provided by the present disclosure can not only maintain or improve the delivery efficiency and the activity of the delivered bioactive agent, but also greatly reduce its toxicity. c Each R is independently selected from a hydroxyl group, a thiol group, a carboxyl group, a phosphate group or a polyethylene glycol group. c In some embodiments, each R b are independently C8-C16 straight chain alkyl. b are the same, for example, each R b All are dodecyl.

[0046] In some embodiments, each R1 is independently selected from H or a group represented by (Ii). Wherein, both R1s may be H, both are groups represented by (Ii), or one R1 is H and the other R1 is a group represented by (Ii). In some embodiments, both R1s are H, in some ways, one R1 is H and the other R1 is a group represented by (Ii), and the R1s described in the present disclosure are c , the amine-containing transfection reagent provided by the present disclosure shows better effects. In some embodiments, each R a In some embodiments, each R a In some embodiments, all Ra are the same, for example, each R a All are pentadecyl.

[0047] In some embodiments, the amine-containing transfection reagent of the present disclosure is selected from one or more of the compounds represented by formula (101)-(103) and pharmaceutically acceptable salts thereof.

[0048]

[0049]

[0050] Among them, the pharmaceutically acceptable salt can be selected from the pharmaceutically acceptable salts commonly used in the art, as long as the salt is within a reasonable medical evaluation range, suitable for contact with human and animal tissues and organs, without showing additional toxicity, irritation, allergic reactions, etc., and consistent with a reasonable benefit / risk ratio. The pharmaceutically acceptable salt can be a pharmaceutically acceptable acid addition salt formed with an organic acid and / or an inorganic acid, such as one or more of acetate, glutamate, lactate, adipate, benzoate, malate, citrate, mandelate, succinate, methanesulfonate, hydrochloride, hydrobromide, sulfate and phosphate.

[0051] Preparation of amine-containing transfection reagents

[0052] The compound represented by formula (I) can be prepared by any reasonable synthetic route.

[0053] For example, in some embodiments, the preparation of the compound of formula (I) at least includes contacting the compound of formula (301) with the compound of formula (701) in an organic solvent, in the presence of an organic base and under coupling reaction conditions, and under conditions sufficient to produce the compound of formula (I), and isolating the compound of formula (I);

[0054]

[0055]

[0056] In formula (301) and formula (701), the groups Y1, Y2, R a The definition and value range of R2 are as mentioned above. 701 For the leaving group.

[0057] The organic solvent may be one or more of halogenated alkyl, ether, nitrile and amide solvents. In some embodiments, the organic solvent is dimethylformamide (DMF). Relative to the compound represented by formula (301), the amount of the organic solvent used may be 4-30 L / mol, for example, 6-20 L / mol. The organic base may be a tertiary amine organic base, such as triethylamine or N,N-diisopropylethylamine (DIPEA). The molar ratio of the organic base to the compound represented by formula (301) is 1:1-20:1, and in some embodiments is 3:1-10:1. In the compound represented by formula (701), the leaving group Z 701 It can be a leaving group commonly used in the art, such as halogen, -OCOR, -OTs, -ONO2 or -OH. In some embodiments, the leaving group Z 701 is a halogen. In some embodiments, the leaving group Z 701 The compound represented by formula (701) can be easily synthesized by a person skilled in the art, or can be commercially obtained. For example, when the leaving group Z 701 When Z is bromine, various compounds of formula (701) can be easily prepared from commercially available 4-bromocrotonic acid methyl ester and fatty alcohols of different carbon chain lengths by an ester exchange method known in the art. In the embodiments of the present disclosure, the molar ratio of the compound of formula (701) to the compound of formula (301) can be 2:1-10:1, for example, 2:1-6:1, depending on the structure of the desired product compound of formula (I). The coupling reaction conditions refer to conditions sufficient to make the leaving group Z 701The conditions for leaving and reacting the compound represented by formula (701) with the compound represented by formula (301) to form a covalent bond, and the conditions sufficient to generate the compound represented by formula (I) refer to the above coupling reaction being fully carried out to a degree sufficient to allow sufficient compounds represented by formula (701) to react with the compound represented by formula (301) to form a covalent bond, thereby generating a reaction of the compound represented by formula (I). In some embodiments, the reaction can be carried out at an appropriate temperature such as 40-90°C for 1-15 hours. In some embodiments, the reaction is carried out at 50°C for 2h. In some embodiments, the progress of the reaction can be monitored by thin layer chromatography or HPLC, and the reaction endpoint can be determined by specific indicators such as the reactant / product content in the reaction mixture. Any suitable separation method can be used to separate the compound represented by formula (I) from the reaction mixture. The reaction product obtained can be a mixture of compounds that all conform to the structure represented by formula (I) but have different numbers of R1. Therefore, in some embodiments, after washing and drying the reaction product, gradient elution with an eluent can be performed on a column chromatography, eluent fractions having a single compound composition can be collected, combined and concentrated to separate a single product, wherein the eluent fractions to be combined can be determined by, for example, real-time detection of whether the collected eluent has a single composition by thin layer chromatography (TLC), HPLC or LC-MS. The eluent can be, for example, a mixed solution of dichloromethane (DCM) and methanol (MeOH), with a volume ratio of dichloromethane to methanol of 50:1-10:1.

[0058] In some embodiments, the method for preparing the compound of formula (301) includes contacting the compound of formula (302) with a deprotection reagent in an organic solvent under deprotection reaction conditions to isolate the compound of formula (301).

[0059]

[0060] The definitions and value ranges of R2, Y1, and Y2 are the same as above. 304 It is an amino protecting group.

[0061] The organic solvent may be one or more of halogenated alkyl, ether, alcohol and amide solvents; in some embodiments, the organic solvent is ethanol or methanol. The amount of the organic solvent used relative to the compound represented by formula (302) may be 4-30 L / mol, for example, 10-25 L / mol. The amino protecting group R 304 It can be various amino protecting groups known to those skilled in the art, such as tert-butyloxycarbonyl (BOC), benzyloxy (CBz), benzyl (Bn), trimethylsilyl, trifluoroacetyl (CF3CO) or acetyl. In some embodiments, two R on the same nitrogen atom 304The groups together form a single divalent protecting group, such as phthaloyl. The deprotecting agent and its amount can be determined according to the amino protecting group R 304 In some embodiments, the amino protecting group is a phthaloyl group, and the deprotecting agent can be, for example, hydrazine hydrate, and the molar ratio of the deprotecting agent to the compound represented by formula (302) can be 4:1-20:1, such as 5:1-8:1. The reaction can be carried out at an appropriate temperature, such as 40-90°C for 1-15 hours. In some embodiments, the reaction is carried out under solvent reflux conditions for 2 hours. In some embodiments, the progress of the reaction can be monitored by chromatography or chromatography-mass spectrometry. Any suitable separation method can be used to separate the compound represented by formula (301) from the reaction product. In some embodiments, the reaction product can be washed and dried, and then separated by, for example, column chromatography from the compound represented by formula (301) produced by the reaction. In some embodiments, the reaction product can be directly used in subsequent reactions without further treatment.

[0062] Those skilled in the art can prepare the compound of formula (302) by any reasonable route. In some embodiments, in the compound of formula (302), Y2 is 2-hydroxy-C2-C6 alkylene, and the preparation method of the compound of formula (302) includes contacting the compound of formula (303) with the compound of formula (703) in an organic solvent in the presence of an organic base and under addition ring-opening reaction conditions, and isolating the compound of formula (302).

[0063]

[0064] Among them, R2, Y1, R 304 The definition and value range of Y are the same as above. 703 It is a covalent bond or a C1-C4 alkylene group.

[0065] The organic solvent may be one or more of halogenated alkyl, ether, alcohol and amide solvents; in some embodiments, the organic solvent is DMF. The amount of the organic solvent used relative to the compound represented by formula (303) may be 4-20 L / mol, for example, 7-15 L / mol. Through ring-opening addition, the oxirane group in the compound represented by formula (703) is ring-opened to form a 2-hydroxyethylene group connected to the amino group, thereby reacting with Y 703The groups together constitute the Y2 group in the compound of formula (302). In some embodiments, the molar ratio of the compound of formula (703) to the compound of formula (303) is 2:1-4:1, for example, 2.6:1-3.2:1. In some embodiments, the organic base is a tertiary amine, such as triethylamine or N,N,-diisopropylethylamine. The molar ratio of the organic base to the compound of formula (303) is 1:1-10:1, in some embodiments, 1.2:1-5:1. The reaction can be carried out at an appropriate temperature, such as 90-150°C for 5-15 hours. In some embodiments, the reaction is carried out at 110-130°C for 6-12 hours. The compound of formula (302) can be separated from the reaction product by any suitable separation method. In some embodiments, the compound of formula (302) produced by the reaction can be separated by, for example, column chromatography after washing and drying. In some embodiments, the reaction product can be directly used in subsequent reactions without further treatment.

[0066] Those skilled in the art can prepare the compound represented by formula (303) by any reasonable route. c All are hydroxyl groups. The preparation method of the compound represented by formula (303) includes contacting the diamine compound represented by formula (304) with the ethylene oxide derivative represented by formula (704) in an organic solvent under addition ring-opening reaction conditions to separate the compound represented by formula (303).

[0067]

[0068] Among them, Y1 and R b The definition and value range of are the same as above.

[0069] The organic solvent may be one or more of halogenated alkyl, ether, alcohol and amide solvents; in some embodiments, the organic solvent is ethanol. The amount of the organic solvent used relative to the compound represented by formula (304) may be 3-20 L / mol, for example, 4-10 L / mol. Through ring-opening addition, the oxirane group in the compound represented by formula (704) is ring-opened to form a 2-hydroxyethylene group connected to the amino group, thereby reacting with R bThe groups together constitute the R2 group in the compound represented by formula (303). Therefore, in some embodiments, the molar ratio of the compound represented by formula (704) to the compound represented by formula (304) is 2:1-4:1, for example, it can be 2.1:1-2.6:1. The reaction can be carried out at an appropriate temperature, such as 25-70°C for 2-10 hours. In some embodiments, the reaction is carried out at 50°C for 4-6 hours. Any suitable separation method can be used to separate the compound represented by formula (303) from the reaction product. In some embodiments, the compound represented by formula (303) can be obtained after filtering, washing, and drying. In some embodiments, the reaction product can be directly used in subsequent reactions without further treatment.

[0070] The compound represented by the above formula (703), the compound represented by the formula (704), and the compound represented by the formula (304) can be easily prepared by a person skilled in the art according to existing public documents, or can be commercially obtained. For example, when Y1 is butylene, the compound represented by the formula (304) is 1,4-butylene diamine which is easily commercially available; when Y1 is butylene, the compound represented by the formula (304) is 1,4-butylene diamine which is easily commercially available; 703 is a methylene group, and the two R 304 When the groups together form a phthaloyl group, the compound represented by formula (703) is commercially available N-(2,3-epoxypropyl)phthalamide; when R b When it is dodecyl, the compound represented by formula (704) is 1,2-epoxytetradecane which is easily commercially available. Unless otherwise specified, other raw materials used in the present disclosure are also commercially available raw materials or raw materials which are easily prepared according to existing disclosures.

[0071] Transfection complex

[0072] In another aspect, the present disclosure provides a transfection complex comprising the amine-containing transfection reagent of the present disclosure.

[0073] The term "transfection complex" as used in this disclosure generally refers to a composition used to deliver a biologically active agent (such as a nucleic acid, a pharmaceutical protein, or a small molecule) to a cell or tissue in vivo or in vitro.

[0074] Considering the sales status, the transfection complex without biologically active agents can be produced and sold as a product alone. Therefore, the transfection complex provided by the present disclosure can contain key lipids, and the key lipid refers to the amine-containing transfection reagent described in the present disclosure.

[0075] In some embodiments, the transfection complex further comprises an auxiliary lipid and / or a pegylated lipid. The molar ratio between the key lipid, the auxiliary lipid and the pegylated lipid can vary over a wide range. In some embodiments, the molar ratio is (15-100): (0-85): (0-50); in some embodiments, the molar ratio is (19.7-80): (19.7-80): (0.3-50); alternatively, the molar ratio can be (50-70): (20-40): (3-30).

[0076] The term "helper lipid" used in the present disclosure generally refers to other auxiliary lipids suitable for preparing and forming transfection complexes in addition to the amine-containing transfection reagents, i.e., key lipids, provided in the present disclosure. Suitable helper lipids can be helper lipids commonly used in the art, for example, the helper lipids are selected from, but not limited to, cholesterol, cholesterol analogs, cholesterol derivatives, sterols (including plant sterols, animal sterols and hopanes), or any one or more of neutral or cationic lipids known to achieve or promote the introduction of exogenous bioactive agents into cells or tissues. In certain embodiments, more than one helper lipid can be used in the formulation of the transfection complex described in the present disclosure. Exemplary, but non-limiting, neutral or cationic lipids that can be used to prepare the transfection complexes provided by the present disclosure can be one or more lipids selected from the following: BMOP (N-(2-bromoethyl)-N,N-dimethyl-2,3-di(9-octadecenyloxy)-propylammonium bromide), DDPES (dipalmitoylphosphatidylethanolamine 5-carboxysperminylamide), DSPC, CTAB:DOPE (a preparation of cetyltrimethylammonium bromide (CATB) and DOPE), POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerate), choline), DOPE (dioleoylphosphatidylethanolamine), DMG, DMAP (4-dimethylaminopyridine), DMPE (dimyristoylphosphatidylethanolamine), DOMG, DMA, DOPC (dioleoylphosphatidylcholine), DMPC (dimyristoylphosphatidylcholine), DPEPC (dipalmitoylethylphosphatidylcholine), DODAC (dioleoyldimethylammonium chloride), DOSPER (1,3-dioleoyloxy-2-(6-carboxysperminyl)-propylamide), DOTMA (N-[1-(2,3-dioleyloxy)-2-(6-carboxysperminyl)-propylamide), )propyl]-N,N,N-trimethylammonium chloride), DDAB (didodecyl methyl ammonium bromide), DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-ammonium methyl sulfate), DOTAP·Cl, DC-chol (3,β-N,(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol), DOSPA (2-(sperminecarboxamido)ethyl)-N,N-dimethyl-ammonium trifluoroacetate), DC-6-14 (O,O′-ditetradecanoyl-N-(α-trimethylammonium acetyl) diethanolamine chloride), DCPE (dihexanoylphosphatidylethanolamine), DLRIE (dilauryloxypropyl-3-dimethylhydroxyethylammonium bromide), DODAP (1,2-dioleoyl-3-dimethylammonium-propane), ethyl-PC, DOSPA (2,3-dioleoyloxy-N-[2-(sperminecarboxamidoethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate), DOGS (dioctadecylamidoglycylcarboxyspermine), DMRIE (N-[1-(2,3-dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl)ammonium bromide), DOEPC (dioleoylethyl-phosphocholine), DOHME (N-[1-(2,3-dioleoyloxy)propyl]-N-[1-(2-hydroxyethyl)]-N,N-dimethylammonium iodide), GAP-DLRIE: DOPE (N-(3-aminopropyl)-N,N-dimethyl-2,3-di(dodecyloxy)-1-propylammonium bromide / dioleylphosphatidylethanolamine), DPPC (dipalmitoylphosphatidylcholine), DOPG (1,2-dioleoyl-sn-glycero-3-[phospho-rac-(3-lysyl(1-glycero))·Cl), N-lauroyl Sarcosine, (R)-(+)-limonene, lecithin (and their derivatives); phosphatidylethanolamine (and their derivatives); phosphatidylethanolamines, dioleoylphosphatidylethanolamine), DPhPE (diphytanoylphosphatidylethanolamine), DPPE (dipalmitoylphosphatidylethanolamine), dipalmitoylphosphatidylethanolamine, O-Chol (3β[1-ornithineamidecarbamoyl]cholesterol), POPE (palmitoyloleoylphosphatidylethanolamine) and distearoylphosphatidylethanolamine; phosphatidylcholine; phosphatidylcholine, DPPC (dipalmitoylphosphatidylcholine), POPC (palmitoyloleoylphosphatidylcholine) and distearoylphosphatidylcholine; phosphatidylglycerol; piperazine-based cationic lipids, phosphatidylglycerols, such as DOPG (dioleoylphosphatidylglycerol), DPPG (dipalmitoylphosphatidylglycerol) and distearoylphosphatidylglycerol; phosphatidylserine (and their derivatives); phosphatidylserines, such as dioleoyl- or dipalmitoylphosphatidylserine; diquaternary ammonium salts such as N,N′-dioleyl-N,N,N′,N′-tetramethyl-1,2-ethylenediamine (TmedEce), N,N′-dioleyl-N,N,N′,N′-tetramethyl-1,3-propylenediamine (PropEce), N,N′-dioleyl-N,N,N′,N′-tetramethyl-1,6-hexanediamine (HexEce) and their derivatives; The corresponding N, N'-dicetyl saturated analogs (TmedAce, PropAce and HexAce), diphosphatidylglycerols; fatty acid esters; monocationic transfection lipids such as 1-deoxy-1-[dihexadecyl (methyl) ammonium]-D-xylitol; 1-deoxy-1-[methyl (ditetradecyl) ammonium]-D arabitol; 1-deoxy-1-[dihexadecyl (methyl) ammonium]-D-arabitol; 1-deoxy-1-[methyl (dioctadecyl) ammonium]-D arabitol, glycerides; sphingolipids; cardolipins; cerebrosides; and ceramides; and mixtures of two or more thereof. Neutral lipids can also be selected from the following commercially available cationic lipid mixtures, for example, (1:1.5 (M / M) preparation of N,NI,NII,NIII-tetramethyl-N,NI,NII,NIII-tetrapalmitospermine (TMTPS) and dioleoylphosphatidylethanolamine (DOPE)), GS2888 and TFXN TM 、TRANSFAST TM , vectamidine (3-tetradecylamino-N-tert-butyl-N′-tetradecylpropionamidine (also known as bis-C14-amidine), And others. Any combination or mixture of the above-listed helper lipids is also expected to be used in the transfection complexes of the present disclosure. The following patent documents, patent applications or references are incorporated by reference in their entirety into the present disclosure, especially their disclosures about transfection agents containing cationic and neutral helper lipids that can be used to form the transfection complexes of the present disclosure: U.S. Patents 6,075,012, 6,020,202, 5,578,475, 5,736,392, 6,051,429, 6,376,248, 5,334,761, 5,316,948, 5,674,908, 5,834, 439, 6,110,916, 6,399,663, 6,716,882, 5,627,159; PCT / US / 2004 / 000430, published as WO04063342A2; PCT / US / 9926825, published as WO0027795A1; PCT / US / 04016406, published as WO04105697; and PCT / US2006 / 019356, published as WO07130073A2.

[0077] The term "PEGylated lipid" used in the present disclosure generally refers to a lipid covalently conjugated to one or more polyethylene glycol moieties. The PEGylated lipids used in the transfection complex embodiments of the present disclosure include: phosphatidylethanolamine (PE)-based PEGylated lipids, for example, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-MW], wherein MW represents the average molar mass of the polyethylene glycol moiety. Such dimyristoyl-PEG-PE lipids are collectively referred to as 14:0PEG(MW)PE. The average MW of the polyethylene glycol moiety can be, for example, 25, 350, 550, 750, 1000, 2000, 3000, 5000, 6000, 8000 or 12000. The fatty acid chains of the PEGylated lipids based on phosphatidylethanolamine can include, for example, 1,2-dioleoyl (such as for 18:1 PEG (MW) PE), 1,2-dipalmitoyl (such as for 16:0 PEG (MW) PE) or 1,2-distearoyl (such as for 18:0 PEG (MW) PE). Other PEGylated lipids based on phosphatidylethanolamine (PE) include, for example, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[MOD (polyethylene glycol) -MW], also known as DSPE-MODPEG (MW), where MOD represents a functional part, such as an amine, biotin, carboxylic acid, folate, maleimide, PDP or carboxyfluorescein part. In these PE-based PEGylated lipids, the average molar mass MW of the polyethylene glycol part can be, for example, 2000 or 5000. The PEGylated lipids used in the embodiments described in the present disclosure also include ceramide-based PEGylated lipids, for example, N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)MW]}, also known as C8PEG(MW)ceramide, where the MW is, for example, 750, 2000, or 5000. Alternatively, the fatty acid moiety can have an N-palmitoyl(C16) group (such as in the case of C16PEG(MW)ceramide). In some embodiments, the PEGylated lipid used in the transfection complexes of the present disclosure is 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine-N-[methoxy(polyethylene glycol)-2000].

[0078] The transfection complex provided by the present disclosure is usually a colloidal preparation, but can also be a dried preparation. The transfection complex provided by the present disclosure is an aggregate, which can be a single-layer or multi-layer liposome, a vesicle, a micelle, or an amorphous aggregate.

[0079] In some embodiments, the transfection complex of the present disclosure further comprises a bioactive agent. The term "bioactive agent" can be a composition, complex, compound or molecule that has a biological effect, or modifies, causes, promotes, enhances, blocks or reduces a biological effect, or enhances or limits the production or activity of a second molecule having a biological effect, reacts with and / or binds to the second molecule. The second molecule can be, but is not necessarily, an endogenous molecule (e.g., a molecule that is normally present in a target cell, such as a protein or nucleic acid). The biological effect can be, but is not limited to: an effect that stimulates or causes an immune response; an effect that affects a biological process in a cell, tissue or organism (e.g., an animal); an effect that affects a biological process in a pathogen or parasite; an effect that produces a detectable signal or causes the production of a detectable signal; an effect that regulates the expression of a protein or polypeptide; an effect that terminates or inhibits the expression of a protein or polypeptide; or an effect that causes or enhances the expression of a protein or polypeptide.

[0080] In some embodiments, suitable bioactive agents may include molecules that are capable of forming a transfection complex with the amine-containing transfection reagent described in the present disclosure and that cause a biological response when delivered to one or more cells or to in vivo or in vitro tissues. The bioactive agent used in the embodiments described in the present disclosure may be a cationic, neutral or anionic agent. In some embodiments, the bioactive agent is a small molecule, a functional oligonucleotide or a drug protein, or a drug precursor or a pharmaceutically acceptable salt of any of them. In the context of the present disclosure, the term "drug precursor" is also referred to as "prodrug" or "prodrug", which refers to a compound obtained by modifying the chemical structure of a drug, which is inactive or less active in vitro, and releases an active drug through enzymatic or non-enzymatic conversion in vivo to exert its pharmacological effect.

[0081] In some embodiments, the bioactive agent can be selected from, but not limited to: nucleic acids, polypeptides, antibodies, oligopeptides, therapeutic peptide or protein molecules, peptide nucleic acids (PNA), cationic, anionic or neutral organic molecules or drugs, or pharmaceutically acceptable salts thereof.

[0082] In some embodiments, the bioactive agent is a functional oligonucleotide, or a prodrug thereof or a pharmaceutically acceptable salt thereof. The functional oligonucleotide can be used to generate stable and specific hybridization with the target sequence, and to up-regulate or down-regulate the expression of the target gene, or to cause mRNA variable splicing, by utilizing RNA activation (RNA activation, RNAa), RNA interference (RNA interference, RNAi), antisense nucleic acid technology or exon skipping technology principles. In some aspects, the functional oligonucleotide can also be a nucleic acid structure that generates stable and specific binding with the target protein, such as an aptamer. In addition, it is easily understood by those skilled in the art that polynucleotides (such as mRNA itself or its fragments) are also suitable for forming transfection complexes with amine-containing transfection reagents provided by the present disclosure to achieve transfection delivery to cells, thereby regulating the expression of proteins transcribed from mRNA. Therefore, in the context, the concept of "functional oligonucleotide" can also cover mRNA or its fragments.

[0083] In some embodiments, the functional oligonucleotide can interact with the target sequence, thereby affecting the normal function of the target sequence molecule, such as causing mRNA breakage or translation repression or exon skipping to trigger mRNA alternative splicing. In some embodiments, the functional oligonucleotide can be substantially complementary to the base of the target sequence, substantially reverse complementary or completely reverse complementary. In some embodiments, the functional oligonucleotide can be complementary to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or more than 99% of the bases of the target sequence, or completely complementary to the target sequence. In some embodiments, the functional oligonucleotide can contain 1, 2 or 3 bases that are not complementary to the target sequence. In some embodiments, the functional oligonucleotide is selected from deoxyribonucleic acid or ribonucleic acid, and deoxyribonucleic acid or ribonucleic acid with modification. In some embodiments, the functional oligonucleotide is single-stranded or double-stranded. In some embodiments, the functional oligonucleotide can be single-stranded DNA, RNA or DNA-RNA chimera (chimera), or double-stranded DNA, RNA or DNA-RNA hybrid (hybrids).

[0084] Thus, in some embodiments, the functional oligonucleotide suitable for inclusion in the transfection complex of the present disclosure may be a small interfering RNA (siRNA), a microRNA (microRNA), an anti-microRNA (antimiR), a microRNA antagonist (antagomir), a microRNA mimic (microRNA mimics), a decoy oligonucleotide (decoy), an immune stimulatory (immune stimulatory), a G-quadruplex, a splice altering body (splice altering), a single-stranded RNA (ssRNA), an antisense nucleic acid (antisense), a nucleic acid aptamer (Nucleic Acid Aptamer), a small activating RNA (saRNA), a stem-loop RNA (stem-loop RNA) or one of DNA. In a further embodiment, the functional oligonucleotide suitable for inclusion in the transfection complex of the present disclosure may be an oligonucleotide disclosed in WO2009082607A2, WO2009073809A2 or WO2015006740A2, the entire contents of which are incorporated into the present disclosure by reference. In some embodiments, the functional oligonucleotide suitable for inclusion in the transfection complex of the present disclosure is a double-stranded oligonucleotide. In some embodiments, the functional oligonucleotide suitable for inclusion in the transfection complex of the present disclosure is siRNA.

[0085] The transfection complex disclosed herein can deliver functional oligonucleotides to cells and regulate the expression of specific genes in these cells, and these cells can be various cells. In some embodiments, the cells are hepatocytes. In some embodiments, the specific genes can be endogenous genes expressed in hepatocytes, or pathogen genes that propagate in hepatocytes. Genes expressed in hepatocytes can be, for example, ApoB, ApoC3, ANGPTL3, PCSK9, SCD1, TIMP-1, Col1A1, FVII, STAT3, p53, HBV, HCV genes. In some embodiments, the genes expressed in hepatocytes are HBV genes, ANGPTL3 genes, or APOC3 genes. In the context of the present disclosure, the above-mentioned gene sequences are well known, for example, the HBV gene refers to the gene whose sequence is shown in Genbank Registration Number NC_003977.1; the ANGPTL3 gene refers to the gene whose mRNA sequence is shown in Genbank Registration Number NM_014495.3; and the APOC3 gene refers to the gene whose mRNA sequence is shown in Genbank Registration Number NM_000040.1.

[0086] In some embodiments, the "target sequence" is a target mRNA. In the context of the present disclosure, "target mRNA" refers to the mRNA corresponding to a gene abnormally expressed in a cell, which can be either the mRNA corresponding to an overexpressed gene or the mRNA corresponding to an underexpressed gene. Since most diseases originate from the overexpression of mRNA, in the present disclosure, the target mRNA particularly refers to the mRNA corresponding to the overexpressed gene. In some embodiments of the present disclosure, corresponding to the above-mentioned abnormally expressed genes, the target mRNA may be the mRNA corresponding to ApoB, ApoC3, ANGPTL3, PCSK9, SCD1, TIMP-1, Col1A1, FVII, STAT3, p53, HBV, HCV genes. In some embodiments, the target mRNA may be the mRNA corresponding to the HBV gene, or the mRNA expressed by the ANGPTL3 gene, or the mRNA expressed by the APOC3 gene.

[0087] Without wishing to be limited, in the following embodiments and examples, the case where the functional oligonucleotide in the transfection complex of the present disclosure is a small interfering RNA (siRNA) is described in detail. This does not mean that the bioactive agent in the transfection complex of the present disclosure can only be siRNA. According to the detailed description of the transfection complex, it can be imagined that other bioactive agents, especially other functional oligonucleotides, will have similar effects when forming a transfection complex with the amine-containing transfection reagent provided by the present disclosure.

[0088] It is well known to those skilled in the art that siRNA contains a nucleotide group as a basic structural unit, and the nucleotide group contains a phosphate group, a ribose group and a base. Usually, the length of an active, i.e., functional siRNA is about 12-40 nucleotides, and in some embodiments, about 15-30 nucleotides. Each nucleotide in the siRNA can be independently a modified or unmodified nucleotide. In order to increase stability, at least one nucleotide in the siRNA is a modified nucleotide.

[0089] The inventors of the present disclosure have found that the siRNA described in the following embodiments has higher activity, higher stability, lower off-target effect and / or lower toxicity, and thus can be used as the bioactive agent in the present disclosure.

[0090] In some embodiments, each nucleotide in the siRNA in the transfection complex of the present disclosure is independently a modified or unmodified nucleotide, and the siRNA contains a sense strand and an antisense strand, wherein the sense strand comprises a nucleotide sequence 1, and the antisense strand comprises a nucleotide sequence 2, and the lengths of the nucleotide sequence 1 and the nucleotide sequence 2 are equal, and are both 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 nucleotides, and are at least partially reverse-complemented to form a complementary double-stranded region, and at least a portion of the nucleotide sequence 2 is complementary to the first nucleotide sequence, and the first nucleotide sequence is a nucleotide sequence in the target mRNA. In some embodiments, the lengths of the nucleotide sequence 1 and the nucleotide sequence 2 are both 19, 20 or 21 nucleotides. In some embodiments, the lengths of the nucleotide sequence 1 and the nucleotide sequence 2 are both 19 nucleotides.

[0091] In some embodiments, the siRNA refers to an siRNA that can inhibit at least 50% hepatitis B virus gene expression, at least 50% angiopoietin-like protein 3 gene expression, or at least 50% apolipoprotein C3 gene expression at a dose of 3 mg / kg (in terms of siRNA). In some embodiments, the siRNA refers to an siRNA that can inhibit at least 55%, 60%, 65%, 70%, 75% or 80% HBV gene, ANGPTL3 gene or APOC3 gene expression at a dose of 3 mg / kg.

[0092] In some embodiments, the nucleotide sequence 1 is equal in length to the first nucleotide sequence and has no more than 3 nucleotide differences; the nucleotide sequence 2 is equal in length to the nucleotide sequence B and has no more than 3 nucleotide differences; the nucleotide sequence B is a nucleotide sequence that is completely reverse complementary to the first nucleotide sequence. Without being limited, these specific nucleotide differences do not significantly reduce the target gene inhibition ability of the transfection complex, and these transfection complexes containing specific nucleotide differences are also within the scope of protection of the present disclosure.

[0093] In some embodiments, the nucleotide sequence 1 and the nucleotide sequence 2 are substantially reverse complementary, substantially reverse complementary, or completely reverse complementary. In the above and below, unless otherwise specified, substantially reverse complementary means that there are no more than 3 base mismatches between the two nucleotide sequences involved; substantially reverse complementary means that there is no more than 1 base mismatch between the two nucleotide sequences; and completely complementary means that there is no base mismatch between the two nucleotide sequences.

[0094] In the above and below, a nucleotide sequence having a nucleotide difference with another nucleotide sequence means that the base type of the nucleotide at the same position of the former is changed compared with the latter. For example, when a nucleotide base in the latter is A, and the corresponding nucleotide base at the same position of the former is U, C, G or T, it is considered that there is a nucleotide difference at that position between the two nucleotide sequences. In some embodiments, when a nucleotide at the original position is replaced by an abasic nucleotide or a nucleotide analog, it can also be considered that a nucleotide difference occurs at that position.

[0095] In some embodiments, the nucleotide sequence 1 differs from the first nucleotide sequence by no more than 1 nucleotide, and / or the nucleotide sequence 2 differs from the nucleotide sequence B by no more than 1 nucleotide. In some embodiments, the nucleotide difference between the nucleotide sequence 2 and the nucleotide sequence B includes the difference in the position of the first nucleotide Z' on the nucleotide sequence 2 in the direction from the 5' end to the 3' end. In some embodiments, in the direction from the 5' end to the 3' end, the last nucleotide Z on the nucleotide sequence 1 is a nucleotide complementary to Z'.

[0096] In some embodiments, the sense strand further contains nucleotide sequence 3, and the antisense strand further contains nucleotide sequence 4, the lengths of nucleotide sequence 3 and nucleotide sequence 4 are equal and both are 1-4 nucleotides, the nucleotide sequence 3 is connected to the 5' end of the nucleotide sequence 1, and the nucleotide sequence 4 is connected to the 3' end of the nucleotide sequence 2, and the nucleotide sequence 4 is complementary to the second nucleotide sequence, which refers to a nucleotide sequence in the target mRNA that is adjacent to the first nucleotide sequence and has the same length as the nucleotide sequence 4. In some embodiments, the nucleotide sequence 3 and the nucleotide sequence 4 are substantially reverse complementary or completely reverse complementary. Therefore, the lengths of the sense strand and the antisense strand can be 19-23 nucleotides.

[0097] In some embodiments, the siRNA further comprises a nucleotide sequence 5, the length of which is 1 to 3 nucleotides, which is connected to the 3' end of the antisense strand, thereby constituting the 3' overhang of the antisense strand; in some embodiments, the length of the nucleotide sequence 5 is 1 or 2 nucleotides. Thus, in some embodiments, the length ratio of the sense strand to the antisense strand of the siRNA can be 19 / 20, 19 / 21, 20 / 21, 20 / 22, 21 / 22, 21 / 23, 22 / 23, 22 / 24, 23 / 24 or 23 / 25.

[0098] In one embodiment, the length of the nucleotide sequence 5 is 2 nucleotides, and in the direction from the 5' end to the 3' end, the nucleotide sequence 5 is 2 consecutive deoxythymine nucleotides, 2 consecutive uracil nucleotides, or complementary to the third nucleotide sequence, and the third sequence refers to a nucleotide sequence in the target mRNA that is adjacent to the first nucleotide sequence or adjacent to the second nucleotide sequence and has a length equal to that of the nucleotide sequence 5. In one embodiment, the ratio of the length of the sense strand and the antisense strand of the siRNA is 19 / 21 or 21 / 23, in which case the siRNA has better target mRNA silencing activity.

[0099] In some embodiments, the nucleotides in the siRNA are each independently a modified or unmodified nucleotide. In some embodiments, the siRNA does not contain a modified nucleotide group; in some embodiments, the siRNA contains a modified nucleotide group.

[0100] Currently, there are a variety of methods in the art that can be used to modify siRNA, such as backbone modification (also known as internucleotide linkage modification, such as phosphate group modification), ribose group modification and base modification (for example, see Watts, JK, GF Deleavey and MJ Damha, Chemically modified siRNA: tools and applications. Drug Discov Today, 2008. 13 (19-20): p. 842-55, the entire contents of which are incorporated into the present disclosure by reference).

[0101] In the context of the present disclosure, the term "modified nucleotide" used refers to a nucleotide whose ribose group is modified, such as a nucleotide or nucleotide analog formed by replacing the 2' hydroxyl group with other groups, or a nucleotide whose base is a modified base.

[0102] In some embodiments of the present disclosure, at least one nucleotide in the sense strand or the antisense strand is a modified nucleotide, and / or at least one phosphate group is a phosphate group with a modified group. In other words, at least a portion of the phosphate group and / or ribose group in the phosphate-sugar backbone of at least one single strand in the sense strand and the antisense strand is a phosphate group with a modified group and / or a ribose group with a modified group (or a modified phosphate group and / or a modified ribose group). In some embodiments of the present disclosure, all nucleotides in the sense strand and / or the antisense strand are modified nucleotides.

[0103] In some embodiments, each nucleotide in the sense strand and the antisense strand is independently a fluorinated modified nucleotide or a non-fluorinated modified nucleotide.

[0104] The fluorinated nucleotide refers to a nucleotide in which the hydroxyl group at the 2′-position of the ribose group of the nucleotide is substituted with fluorine, and has a structure represented by the following formula (207).

[0105] Non-fluorinated modified nucleotides refer to nucleotides or nucleotide analogs formed by replacing the hydroxyl group at the 2' position of the ribose group of the nucleotide with a non-fluorinated group. In some embodiments, each non-fluorinated modified nucleotide is independently selected from one of the nucleotides or nucleotide analogs formed by replacing the hydroxyl group at the 2' position of the ribose group of the nucleotide with a non-fluorinated group.

[0106] Nucleotides in which the hydroxyl group at the 2′ position of the ribose group is replaced by a non-fluorinated group are well known to those skilled in the art, and these nucleotides can be selected from 2′-alkoxy-modified nucleotides, 2′-substituted alkoxy-modified nucleotides, 2′-alkyl-modified nucleotides, 2′-substituted alkyl-modified nucleotides, 2′-amino-modified nucleotides, 2′-substituted amino-modified nucleotides, and 2′-deoxynucleotides.

[0107] In some embodiments, the 2′-alkoxy modified nucleotide is a methoxy modified nucleotide (2′-OMe), as shown in formula (208). The 2′-substituted alkoxy modified nucleotide, for example, can be a 2′-O-methoxyethyl modified nucleotide (2′-MOE), as shown in formula (209). In some embodiments, the 2′-amino modified nucleotide (2′-NH2) is as shown in formula (210). In some embodiments, the 2′-deoxynucleotide (DNA) is as shown in formula (211).

[0108]

[0109] Nucleotide analogs refer to groups that can replace nucleotides in nucleic acids but have structures different from adenine ribonucleotides, guanine ribonucleotides, cytosine ribonucleotides, uracil ribonucleotides or thymine. In some embodiments, the nucleotide analogs can be, for example, isonucleotides, bridged nucleic acid (BNA) nucleotides or acyclic nucleotides.

[0110] BNA nucleotides refer to constrained or inaccessible nucleotides. BNA can contain a five-membered ring, a six-membered ring, or a seven-membered ring with a "fixed" C3'-endosugar condensed bridge structure. The bridge is usually incorporated into the 2'-, 4'-position of the ribose ring to provide a 2', 4'-BNA nucleotide, such as LNA, ENA, cET BNA, wherein LNA is shown in formula (212), ENA is shown in formula (213), and cET BNA is shown in formula (214).

[0111]

[0112] Acyclic nucleotides are a type of nucleotides formed by opening the sugar ring of a nucleotide, such as unlocked nucleic acid (UNA) nucleotides or glycerol nucleic acid (GNA) nucleotides, wherein UNA is shown in formula (215) and GNA is shown in formula (216).

[0113]

[0114]

[0115] Wherein, R is selected from H, OH or alkoxy (O-alkyl).

[0116] Isonucleotides refer to compounds formed by a change in the position of the base on the ribose ring of a nucleotide, for example, a compound formed by the base moving from the 1′-position to the 2′-position or the 3′-position of the ribose ring, as shown in formula (217) or (218).

[0117]

[0118] Wherein, Base represents a base, such as A, U, G, C or T; R is selected from H, OH, F or the non-fluorine group as described above.

[0119] In some embodiments, the nucleotide analog is selected from one of isonucleotides, LNA, ENA, cET, UNA and GNA. In some embodiments, each non-fluorinated modified nucleotide is a methoxy-modified nucleotide, wherein the methoxy-modified nucleotide refers to a nucleotide formed by replacing the 2′-hydroxyl group of the ribose moiety with a methoxy group.

[0120] In the above and below, "fluorinated nucleotides", "2′-fluorinated nucleotides", "nucleotides in which the 2′-hydroxyl group of the ribose group is substituted by fluorine" and "2′-fluororibose" have the same meaning, all referring to compounds in which the 2′-hydroxyl group of the nucleotide is replaced by fluorine and has a structure as shown in formula (207); "methoxy-modified nucleotides", "2′-methoxy-modified nucleotides", "nucleotides in which the 2′-hydroxyl group of the ribose group is substituted by methoxy" and "2′-methoxyribose" have the same meaning, all referring to compounds in which the 2′-hydroxyl group of the ribose group of the nucleotide is replaced by methoxy to form a structure as shown in formula (208).

[0121] In some embodiments, the siRNA is a siRNA with the following modifications: in the direction from the 5′ end to the 3′ end, the nucleotides at positions 7, 8, and 9 of the nucleotide sequence 1 in the sense strand of the siRNA are -fluorinated nucleotides, and the nucleotides at the remaining positions in the sense strand are methoxy-modified nucleotides; in the antisense strand, the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence 2 are fluorinated nucleotides, and the nucleotides at the remaining positions in the antisense strand are methoxy-modified nucleotides; in some embodiments, the siRNA is a siRNA with the following modifications: or in the direction from the 5′ end to the 3′ end, the nucleotides at positions 5, 7, 8, and 9 of the nucleotide sequence 1 in the sense strand of the siRNA are fluorinated nucleotides, and the nucleosides at the remaining positions in the sense strand are methoxy-modified nucleotides. The nucleotides in the sense strand of the siRNA are methoxy-modified nucleotides; in the antisense strand, the nucleotides at positions 2, 6, 8, 9, 14, and 16 of the nucleotide sequence 2 are fluorinated-modified nucleotides, and the nucleotides at the remaining positions in the antisense strand are methoxy-modified nucleotides; in some embodiments, the siRNA is a siRNA with the following modifications: in the direction from the 5′ end to the 3′ end, the nucleotides at positions 7, 8, and 9 of the nucleotide sequence 1 in the sense strand of the siRNA are fluorinated-modified nucleotides, and the nucleotides at the remaining positions in the sense strand are methoxy-modified nucleotides, and, in the direction from the 5′ end to the 3′ end, the nucleotides at positions 2, 6, 14, and 16 of the nucleotide sequence 2 in the antisense strand of the siRNA are fluorinated-modified nucleotides, and the nucleotides at the remaining positions in the antisense strand are methoxy-modified nucleotides.

[0122] In some specific embodiments of the siRNA disclosed herein, the nucleotide contains a phosphate group modification. In the context of the present disclosure, the phosphate group modification is, in one embodiment, a phosphorothioate modification as shown in the following formula (201), i.e., a non-bridging oxygen atom in a phosphodiester bond is substituted with a sulfur atom, thereby replacing the phosphodiester bond with a phosphorothioate diester bond. In some embodiments, this modification can stabilize the structure of the siRNA and maintain high specificity and high affinity for base pairing.

[0123]

[0124] According to some embodiments of the present disclosure, in the siRNA, the phosphorothioate linkage is present in at least one of the group consisting of the following positions: between the first and second nucleotides at either end of the sense strand or the antisense strand; between the second and third nucleotides at either end of the sense strand or the antisense strand; or any combination of the above. In some embodiments, the phosphorothioate linkage is present at all of the above positions except the 5′ end of the sense strand. In some embodiments, the phosphorothioate linkage is present at all of the above positions except the 3′ end of the sense strand. In some embodiments, the phosphorothioate linkage is present at at least one of the following positions:

[0125] The connection between the first nucleotide and the second nucleotide at the 5′ end of the sense strand;

[0126] The connection between the second nucleotide and the third nucleotide at the 5′ end of the sense strand;

[0127] The connection between the first nucleotide and the second nucleotide at the 3′ end of the sense strand;

[0128] The connection between the second nucleotide and the third nucleotide at the 3′ end of the sense strand;

[0129] The connection between the first nucleotide and the second nucleotide at the 5′ end of the antisense strand;

[0130] The connection between the second nucleotide and the third nucleotide at the 5′ end of the antisense strand;

[0131] The connection between the first nucleotide and the second nucleotide at the 3′ end of the antisense strand; and

[0132] The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.

[0133] According to some embodiments of the present disclosure, the 5′-terminal nucleotide of the antisense strand sequence of the siRNA molecule is a 5′-phosphate nucleotide or a 5′-phosphate analog-modified nucleotide.

[0134] In some embodiments, the 5′-phosphate nucleotide may have a structure as shown in formula (202):

[0135]

[0136] Meanwhile, the types of commonly used 5′-phosphate analog-modified nucleotides are well known to those skilled in the art, for example, Anastasia Khvorova and Jonathan K. Watts, The chemical evolution of oligonucleotide therapies of clinical utility Nature Biotechnology, 2017, 35(3): 238-48 disclose the following four nucleotides as shown in formulas (203) to (206):

[0137]

[0138]

[0139] wherein R represents a group selected from the group consisting of H, OH, F and methoxy;

[0140] Base represents a base selected from A, U, C, G or T.

[0141] In some embodiments, the 5′-phosphate nucleotide or the 5′-phosphate analog modified nucleotide is a nucleotide containing vinyl phosphate (E-vinylphosphonate, E-VP) as shown in formula (203), a 5′-phosphate modified nucleotide as shown in formula (202), or a 5′-thiophosphate modified nucleotide as shown in formula (205).

[0142] Tables 1A-1F show siRNAs that can be used as bioactive agents. The transfection complexes provided by the present disclosure using these siRNAs have surprisingly low toxicity while maintaining high activity.

[0143] Table 1A

[0144]

[0145] Table 1B

[0146]

[0147]

[0148] Table 1C

[0149]

[0150]

[0151] Table 1D

[0152]

[0153] Table 1E

[0154]

[0155]

[0156] Table 1F

[0157]

[0158]

[0159] *S: sense strand; AS: antisense strand

[0160] Among them, capital letters C, G, U, and A represent the base composition of the nucleotide; lowercase letter m represents that the nucleotide adjacent to the left of the letter m is a 2′-methoxy-modified nucleotide; lowercase letter f represents that the nucleotide adjacent to the left of the letter f is a 2′-fluorine-modified nucleotide; lowercase letter s represents that the connection between the two nucleotides adjacent to the left and right of the letter s is a phosphorothioate connection; P1 represents that the nucleotide adjacent to the right of P1 is a 5′-phosphate nucleotide or a 5′-phosphate analog modified nucleotide, and in some embodiments is a vinyl phosphate modified nucleotide, a 5′-phosphate modified nucleotide, or a phosphorothioate modified nucleotide.

[0161] It is well known to those skilled in the art that modified nucleotide groups can be introduced into the siRNA described in the present disclosure by using nucleoside monomers with corresponding modifications, and methods for preparing nucleoside monomers with corresponding modifications and methods for introducing modified nucleotide groups into siRNA are also well known to those skilled in the art. All modified nucleoside monomers can be purchased commercially or prepared using known methods.

[0162] In the above and below, when describing the preparation method of the functional oligonucleotide disclosed in the present invention, unless otherwise specified, the nucleoside monomer refers to the "unmodified or modified RNA phosphoramidite" used in the solid phase phosphoramidite synthesis according to the RNA sequence to be prepared, and the solid phase phosphoramidite synthesis is a well-known method for synthesizing RNA in the art. When the RNA is siRNA, the method generally includes, according to the type and order of nucleotides of the sense strand or antisense strand in the siRNA to be prepared, the nucleoside monomers are sequentially connected in the direction of 3' to 5' to synthesize the sense strand and the antisense strand, and the connection of each nucleoside monomer includes four steps of deprotection, coupling, capping, oxidation or sulfurization to obtain the sense strand connected to the solid phase carrier and the antisense strand connected to the solid phase carrier; remove the protecting group and cut with the solid phase carrier, separate and purify respectively, obtain the sense strand or antisense strand of siRNA, and anneal. In the present disclosure, RNA phosphoramidite also refers to nucleoside phosphoramidites. Unless otherwise stated, the nucleoside monomers used in the present disclosure are commercially available.

[0163] Other conditions of the solid phase synthesis, including nucleoside monomer deprotection conditions, deprotection reagent type and amount, coupling reaction conditions, coupling reagent type and amount, capping reaction conditions, capping reagent type and amount, oxidation reaction conditions, oxidation reagent type and amount, sulfurization reaction conditions, sulfurization reagent type and amount adopt various reagents, amounts and conditions conventionally used in the art.

[0164] For example, in some embodiments, the solid phase phosphoramidite synthesis may use the following conditions:

[0165] The nucleoside monomer deprotection conditions include a temperature of 0-50° C., in some embodiments 15-35° C., a reaction time of 30-300 seconds, in some embodiments 50-150 seconds, a deprotection agent can be selected from one or more of trifluoroacetic acid, trichloroacetic acid, dichloroacetic acid, and monochloroacetic acid, in some embodiments dichloroacetic acid. The molar ratio of the deprotection agent to the 4,4′-dimethoxytrityl protecting group on the solid phase carrier can be 2:1-100:1, in some embodiments 3:1-50:1.

[0166] The coupling reaction conditions include a temperature of 0-50°C, in some embodiments 15-35°C, a molar ratio of the nucleic acid sequence connected to the solid phase support to the nucleoside monomer of 1:1-1:50, in some embodiments 1:5-1:15; a molar ratio of the nucleic acid sequence connected to the solid phase support to the coupling reagent of 1:1-1:100, in some embodiments 1:50-1:80, and a reaction time of 200-3000 seconds, for example 500-1500 seconds. The coupling reagent is selected from one or more of 1H-tetrazole, 5-ethylthio-1H-tetrazole, 5-benzylthio-1H-tetrazole, for example 5-ethylthio-1H-tetrazole.

[0167] The capping reaction conditions include a temperature of 0-50° C., in some embodiments 15-35° C., a reaction time of 5-500 seconds, in some embodiments 10-100 seconds, and the selection of the capping reagent is the same as above. The molar ratio of the total amount of the capping reagent to the nucleic acid sequence connected to the solid phase carrier is 1:100-100:1, in some embodiments 1:10-10:1. In the case where the capping reagent uses equimolar amounts of acetic anhydride and N-methylimidazole, the molar ratio of acetic anhydride, N-methylimidazole and the nucleic acid sequence connected to the solid phase carrier can be 1:1:10-10:10:1, in some embodiments 1:1:2-2:2:1.

[0168] The oxidation reaction conditions include a temperature of 0-50° C., in some embodiments 15-35° C., a reaction time of 1-100 seconds, in some embodiments 5-50 seconds, and an oxidizing agent in some embodiments iodine (in some embodiments, provided in the form of iodine water). The molar ratio of the oxidizing agent to the nucleic acid sequence connected to the solid phase carrier in the coupling step can be 1:1-100:1, in some embodiments 5:1-50:1. In some embodiments, the oxidation reaction is carried out in a mixed solvent of tetrahydrofuran: water: pyridine = 3:1:1-1:1:3.

[0169] When the connection between two nucleotides in siRNA is a phosphorothioate connection, the oxidation step is replaced by sulfurization. The sulfurization reaction conditions include a temperature of 0-50°C, in some embodiments 15-35°C, a reaction time of 50-2000 seconds, in some embodiments 100-1000 seconds, and the sulfurization reagent is hydrogenated xanthan in some embodiments. The molar ratio of the sulfurization reagent to the nucleic acid sequence connected to the solid phase carrier in the coupling step is 10:1-1000:1, in some embodiments 10:1-500:1. In some embodiments, the sulfurization reaction is carried out in a mixed solvent of acetonitrile:pyridine=1:3-3:1.

[0170] After all nucleoside monomers are connected and before annealing, the method further includes separating the sense strand and the antisense strand of the siRNA. The separation method is well known to those skilled in the art and generally includes cutting the synthesized nucleotide sequence from the solid phase support, removing the protecting groups on the base and the phosphate group, purifying and desalting.

[0171] The synthesized nucleotide sequence is cut from the solid phase support, and the protecting groups on the base and the phosphate group are removed, which can be carried out according to the conventional cutting and deprotection methods in siRNA synthesis. For example, the obtained nucleotide sequence connected to the solid phase support is contacted with concentrated ammonia water. The concentrated ammonia water can be 25-30% by weight ammonia water, and the amount of concentrated ammonia water used can be 0.2ml / μmol-0.8ml / μmol compared with the target siRNA sequence.

[0172] When there is at least one 2'-TBDMS protection on the synthesized nucleotide sequence, the method further comprises contacting the nucleotide sequence from which the solid phase carrier has been removed with triethylamine trihydrofluoride to remove the 2'-TBDMS protection. At this time, the corresponding nucleotides in the obtained target siRNA sequence have free 2'-hydroxyl groups. The amount of pure triethylamine trihydrofluoride used can be 0.4ml / μmol-1.0ml / μmol compared to the target siRNA sequence. In this way, siRNA that can be used for the transfection complex disclosed in the present invention can be obtained.

[0173] The methods of purification and desalting are well known to those skilled in the art. For example, nucleic acid purification can be completed by using a preparative ion chromatography purification column through gradient elution with NaBr or NaCl; after the products are collected and combined, a reverse phase chromatography purification column can be used for desalting.

[0174] In the siRNA thus obtained, the non-bridging oxygen atoms or sulfur atoms in the phosphodiester bonds or thiophosphodiester bonds between the nucleotides are substantially combined with sodium ions, and the obtained siRNA is substantially present in the form of sodium salts. Other forms of siRNA can be obtained by replacing the sodium ions with hydrogen ions and / or other cations (e.g., other alkali metal ions or ammonium ions) using well-known ion exchange methods.

[0175] During the synthesis process, the purity and molecular weight of the nucleic acid sequence can be tested at any time to better control the synthesis quality. Such testing methods are well known to those skilled in the art. For example, the purity of the nucleic acid can be tested by ion exchange chromatography, and the molecular weight can be determined by liquid chromatography-mass spectrometry (LC-MS).

[0176] Annealing methods are also well known to those skilled in the art. For example, the synthesized sense strand (S strand) and antisense strand (AS strand) can be simply mixed in an equal molar ratio in water for injection and heated to 70-95° C., and then cooled to room temperature to form a double-stranded structure through hydrogen bonds. In this way, siRNA that can be used for the transfection complex of the present disclosure can be obtained.

[0177] After obtaining the siRNA, in some embodiments, the synthesized siRNA can be characterized by, for example, liquid chromatography-mass spectrometry, for example, by molecular weight detection, to determine that the sequence of the synthesized siRNA is the desired siRNA sequence, for example, one of the sequences listed in Table 1.

[0178] In the transfection complex provided by the present disclosure, there may be no bioactive agent, and the content of the bioactive agent may vary within a wide range, as long as it is not harmful to the subject. In some embodiments, the weight ratio of the bioactive molecule to the total lipid in the transfection complex of the present disclosure is in the range of about 1:1-1:200, wherein the total lipid is the sum of the key lipid (i.e., the amine-containing transfection reagent of the present disclosure), the auxiliary lipid and the pegylated lipid. In some embodiments, the weight ratio is in the range of from about 1:1 to about 1:50, from about 1:1 to about 1:30, from about 1:1 to about 1:20, from about 1:2 to about 1:18, from about 1:3 to about 1:17, from about 1:4 to about 1:15, from about 1:5 to about 1:12, from about 1:6 to about 1:12, or from about 1:6 to about 1:10, for example, the weight ratio of the bioactive agent to the total amount of lipid is about 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17 or 1:18.

[0179] In certain non-limiting embodiments, the transfection complex particles formed by the siRNA and the above-mentioned amine-containing transfection reagent have an average diameter of about 30 nm to about 200 nm (i.e., the apparent average particle size), typically about 40 nm to about 135 nm. In some embodiments, the average diameter of the transfection complex particles is about 50 nm to about 120 nm, about 50 nm to about 100 nm, about 60 nm to about 90 nm, or about 70 nm to about 90 nm. For example, the average diameter of the transfection complex particles is about 30, 40, 50, 60, 70, 75, 80, 85, 90, 100, 110, 120, 130, 140, 150 or 160 nm.

[0180] In some embodiments, the transfection complex particles of the present disclosure have a uniform dispersibility (PDI). In some embodiments, the transfection complex particles of the present disclosure have a dispersibility of 0.03-0.5. In some embodiments, the transfection complex particles of the present disclosure have a dispersibility of 0.05-0.35. In some embodiments, the transfection complex particles of the present disclosure have a dispersibility of 0.07-0.166.

[0181] In some embodiments, the transfection complexes of the present disclosure have an encapsulation efficiency of 70.3%-99.9%. In some embodiments, the transfection complexes of the present disclosure have an encapsulation efficiency of 75.0%-99.0%. In some embodiments, the transfection complexes of the present disclosure have an encapsulation efficiency of 79.3%-98.15%.

[0182] In some embodiments, each component of the transfection complex of the present disclosure may exist independently when sold, and may exist in the form of a liquid preparation when used.

[0183] The method for preparing the transfection complex provided by the present disclosure comprises providing a solution containing a key lipid, and incubating the solution containing the key lipid, wherein the key lipid is an amine-containing transfection reagent provided by the present disclosure.

[0184] In some embodiments, the solution containing the key lipid further contains an auxiliary lipid and a PEGylated lipid. The ratio of the key lipid to the auxiliary lipid and the PEGylated lipid is as described above.

[0185] In some embodiments, the method further comprises concentrating or diluting the incubated liposome preparation. In some embodiments, the method further comprises removing impurities and / or sterilizing.

[0186] In some embodiments, the method further comprises mixing the solution containing the key lipid with a solution containing a bioactive agent before incubation. The type and content of the bioactive agent are as described above.

[0187] The solvents and the amounts of the solutions containing the key lipids and the bioactive agents are conventionally selected. Conventional conditions can be used for incubation.

[0188] Concentration or dilution can be performed before, after or simultaneously with the removal of impurities.

[0189] Conventional methods can be used for removing impurities and sterilizing. For example, the impurities can be removed by ultrafiltration using a tangential flow system, a hollow fiber column, under 100K Da conditions, with the ultrafiltration exchange solution being a phosphate buffered saline (PBS) at pH 7.4. Sterilization can be performed by filtration on a 0.22 μm filter.

[0190] In a specific embodiment, taking the bioactive agent as siRNA as an example, the transfection complex provided by the present disclosure can be prepared according to the following method:

[0191] The amine-containing transfection reagent (key lipid), auxiliary lipid and PEGylated lipid provided by the present disclosure are mixed in alcohol according to the above molar ratio to obtain a solution containing the key lipid; the amount of alcohol is such that the total mass concentration of the obtained solution containing the key lipid is 2-25 mg / mL, for example, 8-18 mg / mL. The alcohol is selected from pharmaceutically acceptable alcohols, such as alcohols that are liquid near room temperature. In some embodiments, the alcohol is selected from ethanol, propylene glycol, benzyl alcohol, glycerol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, one or more, for example, ethanol.

[0192] Dissolve siRNA in a buffered saline solution to obtain an siRNA aqueous solution. The concentration of the buffered saline solution is 0.05-0.5M, for example, 0.1-0.2M, and the pH of the buffered saline solution is adjusted to 4.0-5.5, for example, 5.0-5.2. The amount of the buffered saline solution is such that the concentration of siRNA does not exceed 0.6mg / mL, for example, 0.2-0.4mg / mL. The buffered salt is selected from one or more of soluble acetates and soluble citrates, for example, sodium acetate and / or potassium acetate.

[0193] The solution containing the key lipid and the siRNA aqueous solution are mixed, and the product obtained after mixing is incubated at 40-60° C. for at least 2 minutes, for example, 5-30 minutes, to obtain the incubated liposome preparation. The volume ratio of the solution containing the key lipid and the siRNA aqueous solution is 1: (2-5), for example, 1: 4. The incubated liposome preparation is concentrated or diluted, impurities are removed, and sterilization is performed to obtain the transfection complex provided by the present disclosure, wherein the physicochemical parameters of the transfection complex are pH 6.5-8, encapsulation efficiency not less than 80%, particle size 40-200nm, polydispersity index not higher than 0.30, and osmotic pressure 250-400mOsm / kg; for example, the physicochemical parameters can be pH 7.2-7.6, encapsulation efficiency not less than 90%, apparent average particle size (average particle diameter) 60-100nm, polydispersity index not higher than 0.20, and osmotic pressure 300-400mOsm / kg.

[0194] Application of the transfection complex disclosed herein

[0195] In some embodiments, there is provided a use of the transfection complex of the present disclosure in the preparation of a medicament for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in a cell.

[0196] In some embodiments, the present disclosure provides a method for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in a cell, the method comprising administering an effective amount of a transfection complex comprising a bioactive agent of the present disclosure to a subject in need thereof.

[0197] Taking the bioactive agent contained as siRNA as an example, by administering the transfection complex of the present invention to a subject in need, the purpose of treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in cells can be achieved through the mechanism of RNA interference. Therefore, the transfection complex of the present invention can be used to treat and / or prevent pathological conditions or diseases caused by the expression of specific genes in cells, or to prepare drugs for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in cells.

[0198] The specific gene can be an endogenous gene expressed in the cell, or a pathogen gene that propagates in the cell. In some embodiments, the specific gene is selected from ApoB, ApoC3, ANGPTL3, PCSK9, SCD1, TIMP-1, Col1A1, FVII, STAT3, p53, HBV, HCV genes. Accordingly, the bioactive agent is selected from a bioactive agent that can specifically bind to the mRNA corresponding to the above-mentioned gene, such as siRNA targeting the mRNA corresponding to the above-mentioned gene. In some embodiments, the specific gene is selected from the hepatitis B virus gene, the angiopoietin-like protein 3 gene or the apolipoprotein C3 gene. Accordingly, the disease is selected from chronic liver disease, hepatitis, liver fibrosis disease, liver proliferative disease and dyslipidemia. In some embodiments, the dyslipidemia is hypercholesterolemia, hypertriglyceridemia or atherosclerosis. In some embodiments, the transfection complex provided by the present disclosure can also be used to treat other diseases, including diseases characterized by unwanted cell proliferation, blood diseases, metabolic diseases and diseases characterized by inflammation. Proliferative diseases can be benign or malignant diseases, such as cancer or cell tumors. Hematological or inflammatory diseases can be diseases involving coagulation factors, complement-mediated inflammation or fibrosis. Metabolic diseases include dyslipidemia and irregularities in glucose regulation. In some embodiments, diseases are treated by administering one or more oligonucleotides with a high degree of homology to the gene sequences of the participating cells. Some of the selectable bioactive agents have been described in detail above.

[0199] The term "administration / administration" as used in the present disclosure refers to placing the transfection complex of the present disclosure into the body of a subject by a method or approach that at least partially localizes the transfection complex of the present disclosure to a desired site to produce a desired effect. Administration routes suitable for the methods of the present disclosure include local administration and systemic administration. In general, local administration results in more transfection complexes being delivered to a specific site compared to the subject's systemic circulation; while systemic administration results in the delivery of the transfection complex of the present disclosure to the subject's systemic circulation.

[0200] The drug may be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, such as intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration, and topical administration (including oral administration and sublingual administration). The frequency of administration may be once or more per day, per week, every two weeks, every three weeks, every month, or every year.

[0201] The dosage of the transfection complex described in the present disclosure can be a conventional dosage in the art, which can be determined based on various parameters, especially the age, weight and gender of the subject. Toxicity and efficacy can be determined by standard pharmaceutical procedures in cell culture or experimental animals, such as determining LD 50 (lethal dose that kills 50% of the population) and ED 50 (For quantitative responses this is the dose that induces a 50% maximal response and for qualitative responses this is the dose that induces a positive response in 50% of the subjects.) The range of dosage for human use can be derived based on data from cell culture assays and animal studies.

[0202] When administering the transfection complex described in the present disclosure, for example, for male or female BALB / c mice or CD1 mice, which are 6-12 weeks old and weigh 18-25 g, the amount of siRNA used in the transfection complex of the present disclosure containing siRNA can be 0.001-50 mg / kg body weight, in some embodiments, 0.01-10 mg / kg body weight, in some embodiments, 0.05-5 mg / kg body weight, and in some embodiments, 0.1-3 mg / kg body weight.

[0203] In some embodiments, the present disclosure provides a method for inhibiting the expression of a specific gene in a cell, the method comprising contacting an effective amount of the transfection complex of the present disclosure with the cell, introducing the transfection complex of the present disclosure into the cell, and causing the bioactive agent in the transfection complex to enter the cell, thereby inhibiting the expression of the specific gene. In some embodiments, the cell is a hepatocyte. In some embodiments, the hepatocyte can be selected from SMMC-7721, HepG2, Huh7 hepatoma cell lines or isolated primary liver cells. In some embodiments, the cell is an isolated primary liver cell.

[0204] The method provided by the present disclosure is adopted to suppress the expression of a specific gene in a cell, and the amount of the bioactive agent, especially the functional oligonucleotide in the transfection complex provided is easily determined by those skilled in the art according to the effect obtained by expectation. For example, in some embodiments, the functional oligonucleotide is siRNA, and the amount of siRNA in the transfection complex provided comprising siRNA is generally such an amount: the amount of the siRNA is enough to reduce the expression of the target gene, and causes an extracellular concentration of 1pM to 1 μM, or 0.01nM to 100nM, or 0.05nM to 50nM, or 0.05nM to about 5nM at the target cell surface. The amount required to reach the local concentration will vary with various factors, including, for example, delivery method, delivery site, the number of cell layers between the delivery site and the target cell or tissue, and delivery route (local or systemic). The concentration at the delivery site can be significantly higher than the concentration at the surface of the target cell or tissue.

[0205] Beneficial Effects

[0206] In some embodiments, the present disclosure provides transfection complexes with unexpectedly low toxicity and higher or at least comparable activity in vivo compared to transfection complexes described in the prior art.

[0207] According to some embodiments of the present disclosure, the transfection complex containing siRNA provided by the present disclosure shows excellent target gene inhibition effect. For example, according to one embodiment of the present disclosure, the transfection complex containing siRNA for ApoB gene expression provided by the present disclosure shows excellent characteristics of inhibiting ApoB gene expression: while having low off-target effects, it can inhibit 93.89%-94.30% of ApoB gene expression in the liver of BALB / c mice at a dose of 1 mg / kg. At the same time, the transfection complex containing siRNA provided by the present disclosure can also effectively reduce the blood lipid level in BALB / c mice, and at a dose of 1 mg / kg, it can be close to the serum CHO and TG inhibition level in the case of transfection with the transfection complex of the prior art, and can even reach a higher inhibition level. At the same time, compared with the prior art, the transfection complex containing siRNA provided by the present disclosure also shows unexpectedly low acute liver toxicity, especially compared with the transfection complex of the prior art, the organ lesions observed in the gross anatomy occur at a higher concentration, and the maximum tolerated dose (MTD) is increased to at least 1.4 times, or even 2.9 times, of the transfection complex of the prior art. At the same time, when the experimental animals given the transfection complex of the prior art have shown obvious toxic pathological phenomena, such as liver discoloration and ascites, the gross anatomy of the experimental animals given the same dose of the transfection complex of the present disclosure unexpectedly does not show obvious abnormalities. Therefore, the amine-containing transfection reagent and transfection complex of the present disclosure show excellent potential in the in vivo transfection delivery of bioactive agents, especially functional oligonucleotides.

[0208] Reagent test kit

[0209] The present disclosure provides a kit comprising an effective amount of the transfection complex of the present disclosure.

[0210] In some embodiments, the kit described in the present disclosure may provide a transfection complex in one container. In some embodiments, the kit described in the present disclosure may include a container for providing a pharmaceutically acceptable excipient. In some embodiments, the kit may also include other ingredients, such as stabilizers or preservatives. In some embodiments, the kit described in the present disclosure may include at least one other therapeutic agent in a container other than the container providing the bioactive agent described in the present disclosure. In some embodiments, the kit may provide each or more components of the transfection complex in different containers. In some embodiments, the kit may include instructions for mixing each or more components of the transfection complex to obtain the transfection complex of the present disclosure.

[0211] In the kit of the present disclosure, the transfection complex or its components can be provided in any form, such as liquid form, dry form or lyophilized form. In some embodiments, the transfection complex or its components are substantially pure and / or sterile. In some embodiments, sterile water can be provided in the kit of the present disclosure.

[0212] The present disclosure will be further described below by way of examples, but the present disclosure is not limited thereby.

[0213] Example

[0214] The present disclosure will be described in detail below through examples. Unless otherwise specified, the reagents and culture media used in the following examples are all commercially available products, and the experimental operations used, such as nucleic acid electrophoresis and real-time PCR, are all performed according to the methods described in Molecular Cloning (Cold Spring Harbor Laboratory Press (1989)).

[0215] Unless otherwise stated, the animal models used were as follows:

[0216] CD1 mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.;

[0217] BALB / c mice: 6-8 weeks old, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0218] Example 1 Amine-containing transfection reagent and its preparation

[0219]

[0220] (1-1) Preparation of compound of formula N5_1

[0221] To 10g of 1,4-butanediamine (113.4mmol, 1.0eq), add 500ml of anhydrous ethanol. Heat at 50°C until all the solid is dissolved, add 52.9g of 1,2-epoxytetradecane (245.4mmol, 2.2eq), and continue to react at 50°C for 5h. The reaction solution is cooled to room temperature, filtered to dryness, and the filter cake is washed twice with ethanol, 10ml of ethanol each time, and dried to obtain a compound of formula N5_1 (27g). The obtained product has a structure shown in formula (303), wherein Y1 is butylene and R2 is 2-hydroxytetradecyl. Mass spectrometry detection results: ([M+H] + ): Theoretical: 513.53; Actual: 513.47.

[0222] (1-2) Preparation of compound of formula N5_2

[0223] To 11g of N5_1 (21.4mmol, 1.0eq) obtained in step (1-1), 12.2g of N-(2,3-epoxypropyl)phthalamide (60.0mmol, 2.8eq), 4.1g of diisopropylethylamine (DIEA, 32.1mmol, 1.5eq) and 150ml of DMF were added. The reaction was carried out at 120°C for 6h and the reaction was continued overnight. The reaction solution was cooled to room temperature and poured into 1L of water. The aqueous layer was discarded, 50ml of water and 30ml of dichloromethane (DCM) were added to the residue, the organic layer was separated, and the aqueous layer was further extracted once with 20ml of DCM. The organic layers were combined, the solvent was evaporated to dryness, filtered and dried to obtain a compound of formula N5_2 (18g, 91.8%). The obtained product has the structure shown in formula (302), wherein the two R on the same nitrogen atom 304 Together they form a phthaloyl protecting group, and Y2 is a 2-hydroxypropylene group. Mass spectrometry results: ([M+H] + ): Theoretical: 919.64; Actual: 919.59. The crude product was directly used in the next step without further purification.

[0224] (1-3) Preparation of compound of formula N5

[0225] To 18g of N5_2 (19.6mmol.1.0eq) obtained in step (1-2), 6.9g of 85wt% hydrazine hydrate (117.6mmol, 6.0eq) and 400ml of anhydrous ethanol were added. Heat and reflux for 2h. The reaction solution was cooled to 0°C, filtered, the filter cake was washed with ethanol, the mother liquor was combined, concentrated and filtered to dryness to obtain a crude product N5 (13g). The obtained product has a structure shown in formula (301), wherein Y2 is 2-hydroxypropylene. Mass spectrometry detection results: ([M+H]+): Theoretical: 659.63; Actual: 659.61. The crude product was directly put into the next step without further purification.

[0226] (1-4) Amine-containing transfection reagents and their preparation

[0227]

[0228] To 1.4 g of N5 (2.12 mmol, 1.0 eq) obtained in step (1-3), 1.23 g of DIEA (9.54 mmol, 4.5 eq) and 15 ml of DMF were added, and 2.1 g of compound C1 (4-bromocrotonate tetradecyl ester, 5.52 mmol, 2.6 eq) was added to the obtained solution, and the mixture was reacted at 50° C. for 2 h. The reaction solution was cooled to room temperature and poured into 1 L of water, the aqueous layer was discarded, the residue was added into 50 ml of water, and dissolved by stirring with 30 ml of DCM, the organic layer was separated, the aqueous layer was extracted twice with 20 ml of DCM, the organic layers were combined, dried, filtered, and the solvent was evaporated to dryness. The product was eluted by silica gel column chromatography (eluent: DCM: MeOH = 50: 1-10: 1 (v / v)), and the eluted chromatography fractions were collected in sequence using a plurality of labeled sample tubes. TLC was used to determine in real time whether the eluent had a single composition, and the chromatography fractions having the same single composition were combined to obtain three sample components each having a single composition. The eluent was concentrated to remove the eluent to obtain amine-containing transfection reagent 1 (280 mg, purity 92.0%), amine-containing transfection reagent 2 (300 mg, purity 91.7%), and amine-containing transfection reagent 3 (110 mg, purity 85.6%). The purity was detected by HPLC, and the molecular weight was detected by mass spectrometry, confirming that amine-containing transfection reagent 1, amine-containing transfection reagent 2, and amine-containing transfection reagent 3 were amine-containing transfection reagents having the structure represented by formula (101), (102), or (103), respectively.

[0229] Example 2 Preparation of transfection complex

[0230] 1) Biologically active agent siRNA and its synthesis

[0231] siRNA1 and siRNA2 were synthesized as shown in Table 2-1.

[0232] Table 2-1 siRNA sequences

[0233]

[0234] *SS: sense strand; AS: antisense strand

[0235] Note: Capital letters C, G, U, and A represent the base composition of nucleotides; lowercase letter m represents that the nucleotide adjacent to the left of the letter m is a 2′-methoxy-modified nucleotide; lowercase letter f represents that the nucleotide adjacent to the left of the letter f is a 2′-fluorine-modified nucleotide; the letter combination dT represents thymidine deoxynucleotide.

[0236] Except for the above-mentioned differences in sequence, the synthesis conditions of siRNA1 and siRNA2 are exactly the same. The specific synthesis method is as follows:

[0237] Through the method of phosphoramidite nucleic acid solid phase synthesis, using a universal solid phase carrier ( UnyLinker TM 300 Oligonucleotide Synthesis Support, Kinovate Life Sciences, the structure is shown in formula B80) to start the cycle of synthesizing the positive chain:

[0238]

[0239] According to the above sequence, nucleoside monomers are connected one by one in the 3'-5' direction. Each connection of a nucleoside monomer includes four steps of deprotection, coupling, capping, and oxidation. The synthesis conditions are given as follows:

[0240] The nucleoside monomer was provided in a 0.1 M acetonitrile solution. The conditions of the deprotection reaction in each step were the same, i.e., the temperature was 25° C., the reaction time was 70 seconds, the deprotection reagent was a dichloroacetic acid solution in dichloromethane (3% v / v), and the molar ratio of dichloroacetic acid to the 4,4′-dimethoxytrityl protecting group on the solid phase carrier was 5:1.

[0241] The coupling reaction conditions for each step were the same, including a temperature of 25° C., a molar ratio of the nucleic acid sequence connected to the solid phase support to the nucleoside monomer of 1:10, a molar ratio of the nucleic acid sequence connected to the solid phase support to the coupling reagent of 1:65, a reaction time of 600 seconds, and a coupling reagent of 0.5 M acetonitrile solution of 5-ethylthio-1H-tetrazole.

[0242] The capping conditions in each step are the same, including a temperature of 25°C and a reaction time of 15 seconds. The capping reagent solution is a mixed solution of Cap1 and Cap2 in a molar ratio of 1:1, wherein Cap1 and Cap2 are capping reagent solutions, Cap1 is a 20% (v / v) N-methylimidazole pyridine / acetonitrile mixed solution, and the volume ratio of pyridine to acetonitrile is 3:5; Cap2 is a 20% (v / v) acetic anhydride acetonitrile solution; the molar ratio of the capping reagent to the nucleic acid sequence connected to the solid phase carrier is acetic anhydride: N-methylimidazole: nucleic acid sequence connected to the solid phase carrier = 1:1:1.

[0243] The oxidation reaction conditions in each step were the same, including a temperature of 25° C., a reaction time of 15 seconds, and an oxidizing agent of 0.05 M iodine water. The molar ratio of iodine to the nucleic acid sequence connected to the solid phase support in the coupling step was 30:1. The reaction was carried out in a mixed solvent of tetrahydrofuran: water: pyridine = 3:1:1.

[0244] The cleavage and deprotection conditions are as follows: the synthesized nucleotide sequence connected to the carrier is added to 25wt% ammonia water, the amount of ammonia water is 0.5ml / μmol, the reaction is carried out at 55°C for 16h, the liquid is removed, and the product is concentrated to dryness in vacuo. After the ammonia treatment, the product is dissolved with 0.4ml / μmol N-methylpyrrolidone relative to the amount of single-stranded nucleic acid, and then 0.3ml / μmol triethylamine and 0.6ml / μmol triethylamine trihydrofluoride are added to remove the 2′-TBDMS protection on the ribose. Purification and desalting: The nucleic acid is purified by gradient elution of NaCl using a preparative ion chromatography purification column (Source 15Q). Specifically, the eluent A: 20 mM sodium phosphate (pH 8.1), the solvent is water / acetonitrile = 9:1 (volume ratio); the eluent B: 1.5 M sodium chloride, 20 mM sodium phosphate (pH 8.1), the solvent is water / acetonitrile = 9:1 (volume ratio); the elution gradient: eluent A: eluent B = 100:0-50:50 gradient elution. The product eluate is collected and combined, and desalted using a reverse phase chromatography purification column. The specific conditions include using a Sephadex column for desalting, the filler is Sephadex G25, and eluting with deionized water.

[0245] Detection: Ion exchange chromatography (IEX-HPLC) was used for detection; liquid chromatography-mass spectrometry (LC-MS) was used for molecular weight analysis.

[0246] Thus, the siRNA sense strand SS is obtained in this step.

[0247] Using a universal solid phase carrier (UnyLinker TM loaded Solid Supports, Kinovate Life Sciences, Inc.) were used to synthesize the antisense strand AS of siRNA. The deprotection, coupling, capping, oxidation reaction conditions, deprotection and cleavage, and separation conditions in the solid phase synthesis method were the same as those for synthesizing the sense strand to obtain the siRNA antisense strand AS.

[0248] Detection: Purity was determined by ion exchange chromatography (IEX-HPLC); molecular weight was analyzed by liquid chromatography-mass spectrometry (LC-MS).

[0249] The SS chain and the AS chain were dissolved in water for injection to obtain a 40 mg / ml solution, mixed in an equimolar ratio, heated at 50°C for 15 minutes, and cooled to room temperature to obtain siRNA1 and siRNA2.

[0250] The siRNA was diluted to a concentration of 0.2 mg / mL using ultrapure water (Milli-Q ultrapure water instrument, resistivity 18.2 MΩ*cm (25°C)). The molecular weight was detected using a liquid chromatography-mass spectrometer (LC-MS, Liquid Chromatography-Mass Spectrometry, purchased from Waters, model: LCT Premier) to confirm that the obtained siRNA1 and siRNA2 had the nucleic acid sequences listed in Table 2-2.

[0251] 2) Transfection complex containing siRNA1 and its preparation

[0252] A) Preparation of amine-containing transfection reagent solutions: The above-obtained amine-containing transfection reagents 1-3 and one of the comparative amine-containing transfection reagents LC8, cholesterol, and pegylated lipids (1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine-N-[methoxy(polyethylene glycol)-2000 (DPPE-PEG)) were mixed with ethanol at a molar ratio of 52:20:28 to obtain four amine-containing transfection reagent ethanol solutions containing amine-containing transfection reagents 1-3 and LC8, respectively. The concentration of the amine-containing transfection reagent in the four amine-containing transfection reagent ethanol solutions was 6.50 μM.

[0253] Among them, the comparative amine-containing transfection reagent LC8 is a cationic lipid 87 prepared according to Example 12 in Chinese Patent CN 103380113B. The amine-containing transfection reagent has a structure as shown in formula (901):

[0254]

[0255] B) Preparation of siRNA solution

[0256] siRNA1 was dissolved in 200 mM sodium acetate (pH 5.2) solution to obtain a sodium acetate aqueous solution of siRNA1 at a concentration of 0.4 mg / ml.

[0257] C) Preparation of transfection complexes

[0258] The 4 amine-containing transfection reagent ethanol solutions obtained in A) were mixed with the siRNA1 sodium acetate aqueous solution obtained in B) under stirring. The flow rate of the amine-containing transfection reagent ethanol solution was 1 ml / 20s, and the flow rate of the siRNA1 sodium acetate aqueous solution was 4 ml / 20s. The stirring speed was 1000-1500 rpm. The obtained products were incubated in a 50°C water bath for 10 minutes. After incubation, ultrafiltration was performed in a tangential flow system using a hollow fiber column 100K Da, and the ultrafiltration exchange solution was PBS at pH 7.4. The ultrafiltration product was sterilized by filtration on a 0.22μm filter. Aqueous solutions of transfection complexes 1-3 and comparative transfection complex 1 were obtained respectively.

[0259] 3) siRNA2-containing transfection complex and its preparation

[0260] An amine-containing transfection reagent solution was prepared in the same manner as in A) in 2), except that the amine-containing transfection reagents used were amine-containing transfection reagent 1-2 and comparative amine-containing transfection reagent LC8, to obtain three amine-containing transfection reagent ethanol solutions containing amine-containing transfection reagent 1-2 and LC8, respectively.

[0261] The siRNA solution was prepared in the same manner as in 2) B), except that siRNA2 was used instead of siRNA1 to obtain a siRNA2 sodium acetate aqueous solution.

[0262] The transfection complex was prepared according to the same method as in 2) C), except that the three amine-containing transfection reagent ethanol solutions respectively containing amine-containing transfection reagents 1-2 and LC8 obtained above were used instead of the four amine-containing transfection reagent ethanol solutions, and the siRNA2 sodium acetate aqueous solution was used instead of the siRNA1 sodium acetate aqueous solution, to obtain transfection complex 4, transfection complex 5 and comparison transfection complex 2.

[0263] The encapsulation efficiency, apparent average particle size (average particle diameter), dispersibility and siRNA concentration of transfection complex 1-5 and comparative transfection complex 1-2 were measured. The test results are shown in Table 2-2.

[0264] Table 2-2

[0265]

[0266] The encapsulation efficiency was detected by RiboGreen method, and the reagents used (Quant-iT TMRNA Reagent and Kit) was purchased from Thermo Fisher (Invitrogen), catalog number R11490. The fluorescence intensity of siRNA in the sample was detected according to the instructions, and the encapsulation efficiency was calculated according to the method described in the literature (J. Heyes et al, Journal of Controlled Release, 107 (2005): 276-287):

[0267] Encapsulation efficiency = [(fluorescence intensity of the Triton-treated group - fluorescence intensity of the non-Triton-treated group) / fluorescence intensity of the Triton-treated group] × 100%

[0268] The apparent average particle size and dispersity were measured by light scattering (ZetaPALS, Brookhaven Instruments) according to the instrument manual, and the siRNA concentration was determined by NANO DROP 2000 (Thermo).

[0269] According to the siRNA concentration and transfection complex composition in Table 2-2, the weight ratio of siRNA to total lipid in transfection complex 1-5 and comparison transfection complex 1-2 is shown in Table 2-3:

[0270] Table 2-3

[0271]

[0272] Example 3 Inhibition of ApoB mRNA expression and effects of transfection complex on blood lipids

[0273] (1) Drug administration method for mice

[0274] Female BALB / c mice aged 6-8 weeks and weighing 18-25g were randomly divided into 13 groups, which were recorded as negative control group (1 group, given 1×PBS solution), positive control group (3 groups, given different doses of control transfection complex 1), and experimental group (3×3 groups, given different doses of transfection complex 1, transfection complex 2 or transfection complex 3), including 6 mice in negative control group, 5 mice in each positive control group and experimental group. The administration method was a single tail vein administration, the dosage (in terms of siRNA) was 1mg / kg, 0.5mg / kg, 0.1mg / kg, and the administration volume was 10mL / kg. Orbital blood was collected 24h after administration, and then the animals were killed, the animals were grossly dissected and the organs were observed, liver tissues were collected, and RNA later (Sigma Aldrich) was used to preserve them for testing;

[0275] (2) Detection of ApoB mRNA expression level in mouse liver tissue

[0276] For each of the positive control group and experimental group, 1 ml / gRNA Vzol was added to the liver tissue to be tested, and steel beads were added to homogenize in a Tissuelyset II fully automatic tissue homogenizer for 1 minute; 0.2 ml chloroform was added to the homogenized sample, oscillated for 15 seconds, and allowed to stand for 3 minutes; centrifuged at 12000 rpm for 15 minutes at 4°C, and the supernatant was collected; 0.5 mL isopropanol was added to the supernatant, mixed, and allowed to stand at room temperature for 10 minutes; centrifuged at 12000 rpm for 10 minutes at 4°C, and the supernatant was discarded; 1 mL 75% alcohol was added to wash the precipitate, centrifuged at 12000 rpm for 5 minutes at 4°C, and the supernatant was discarded; dried, and 150 μL DEPC water was added to dissolve. The total RNA extracted from mouse liver tissue was obtained.

[0277] The concentration of the extracted total RNA was determined using NANO DROP 2000 (Thermo), and 1% agarose gel electrophoresis (Agarose, OXOID Lot: 1315449) was performed to detect the quality of the extracted total RNA.

[0278] RNA electrophoresis conditions: 1% gel, 0.8 μg sample, Marker: 1 Kb DNA ladder (TRANS, Lot#I11112, Code: #BM201), 90 V, 20 minutes.

[0279] Real-time fluorescence quantitative PCR was used to detect the expression level of ApoB mRNA in liver tissue. Specifically, the extracted total RNA was reverse transcribed into cDNA using the ImProm-IITM reverse transcription kit (Promega) according to its instructions, and then the expression levels of ApoB and GAPDH mRNA in liver tissue were detected using a fluorescence quantitative PCR kit (Beijing Kangwei Century Biotechnology Co., Ltd.), and the inhibition efficiency of siRNA on ApoB mRNA expression in liver tissue was calculated. In this fluorescence quantitative PCR method, the GAPDH gene was used as an internal reference gene, and the mRNA expression levels of ApoB and GAPDH were detected using primers for ApoB and primers for GAPDH.

[0280] Table 3 Primers and base sequences

[0281]

[0282] After the PCR reaction, the product was subjected to 1% agarose gel electrophoresis (Agarose, OXOID Lot: 1315449) to detect the amplification quality. Electrophoresis conditions: 1% gel, 6 μL loading, Marker: 100Kb DNA ladder (TRANS, Lot#K21022, Code: #BM301), 120V, 25 minutes.

[0283] Wherein, ApoB mRNA expression level = (ApoB mRNA expression level of the test group / GAPDH mRNA expression level of the test group) / (ApoB mRNA expression level of the control group / GAPDH mRNA expression level of the control group) × 100%,

[0284] Inhibition rate = [1-(ApoB mRNA expression level in the test group / GAPDH mRNA expression level in the test group) / (ApoB mRNA expression level in the control group / GAPDH mRNA expression level in the control group)] × 100%, where the inhibition rate refers to the inhibition rate of the transfection complex on the expression of ApoB mRNA

[0285] The inhibition rates of transfection complexes prepared with different doses of the disclosed compounds and the comparative transfection complexes on the expression level of ApoB mRNA in liver tissue of BALB / c mice are shown in FIG. Figure 1 and Figure 2 shown.

[0286] Depend on Figure 1 and Figure 2 The results show that in mice, the ApoB mRNA inhibition activity of transfection complexes 1 and 2 is close to or even better than that of the control transfection complex 1 at the same dose. At a low dose (0.1 mg / kg), transfection complex 2 showed an unexpectedly higher ApoB mRNA inhibition rate compared to the control transfection complex 1. The ApoB mRNA inhibition rate of transfection complex 2 was 126.3% of that of the control transfection complex 1.

[0287] (3) Blood lipid concentration detection

[0288] For the experimental subjects given the control transfection complex 1 and transfection complex 1-3, the experimental animals in the 1 mg / kg dose group and the experimental animals in the negative control group given 1×PBS, the blood collected from the orbits was centrifuged according to the groups to obtain serum, and the total cholesterol (CHO) and triglyceride (TG) content in the serum were further detected using PM1P000 / 3 fully automatic serum biochemical analyzer (SABA, Italy). The test results are shown in Figure 3 and Figure 4 middle.

[0289] Depend on Figure 3 and Figure 4 The results show that the CHO and TG levels in the serum of mice treated with transfection complexes 1-3 were significantly decreased, and showed a lipid-lowering effect at least close to that of the control transfection complex 1 at the same dose. In particular, the total cholesterol concentration of mice treated with transfection complex 1 was unexpectedly significantly lower than that of mice treated with the control transfection complex 1, showing a significantly higher lipid-lowering effect.

[0290] Example 4 Acute toxicity test of transfection complexes 4-5 and comparison transfection complex 2 in CD1 mice

[0291] This example is used to detect the toxicity of transfection complexes 4-5 obtained in Example 2 and the comparative transfection complex 2 in CD1 mice.

[0292] CD1 mice aged 6-8 weeks and weighing 18-25 g were randomly divided into positive control group (comparative transfection complex 2) and experimental group (transfection complex 4 and transfection complex 5), with 6 mice in each group (3 males and 3 females, marked as M and F, respectively). Comparative transfection complex 2, transfection complex 4 or transfection complex 5 were administered to each group of mice according to the dosage values ​​listed in Table 4.

[0293] The dosage of all animals was calculated according to their body weight, and a single dose was administered by tail vein injection. The toxicity reaction was observed within 24 hours after administration, and the observation was continued for 96 hours, and the toxicity and death were recorded and autopsied. The results are shown in Table 4.

[0294] Table 4 Transfection complex toxicity test

[0295]

[0296]

[0297] In the column "Summary of Death", M and F respectively indicate the sex of the mice, and the numbers before M and F indicate the number of deaths. For example, "1F" indicates the death of a female mouse, and "3M, 3F" indicates the death of three male mice and three female mice. In the column "Autopsy", the number group with a slash " / " indicates the number of mice that survived and had local liver discoloration. The number after the slash " / " indicates the number of surviving mice in this group of test mice, and the number before the slash " / " indicates the number of mice with local liver discoloration in this group of surviving mice. The preceding text indicates the degree of liver discoloration. For example, "2 / 6 local liver discoloration" indicates that 2 of the 6 mice that survived to the end had local liver discoloration.

[0298] From the results in Table 4, we can see that:

[0299] For the experimental animal group given the control transfection complex 2, no animal deaths occurred in the 9.5 mg / kg dose group, and obvious toxic reactions were observed but no serious organ lesions; animal deaths occurred in the dose groups after the 10.8 mg / kg dose group where animal deaths first occurred, and all animals died in the 30.4 mg / kg dose group, and different degrees of liver discoloration and ascites lesions were found in the surviving animals in other dose groups during autopsy.

[0300] For the experimental animal group administered with transfection complex 4, the first animal death occurred in the 15.2 mg / kg dose group; compared with the experimental animal group administered with the control transfection complex 2 at the same dose, no obvious abnormality was shown in the liver in the 13.0 mg / kg dose group.

[0301] For the experimental animal group administered with transfection complex 5, the first animal death occurred in the 27.4 mg / kg dose group; compared with the experimental animal group administered with the control transfection complex 2 at the same dose, no obvious abnormality was shown in the liver in the 15.2 mg / kg dose group, and especially compared with the experimental animal group administered with the control transfection complex 2, surprisingly, no animal died in the 30.4 mg / kg dose group.

[0302] Therefore, the maximum tolerated dose (MTD) of each transfection complex is roughly estimated as follows:

[0303] Comparative transfection complex 2: 9.5-10.8 mg / kg;

[0304] Transfection complex 4: 13.7-15.2 mg / kg;

[0305] Transfection complex 5: 15.2-27.4 mg / kg.

[0306] It can be seen that compared with the control transfection complex, the transfection complex of the present invention shows lower acute toxicity at the same dose, and in terms of the maximum tolerated dose, the transfection complex of the present invention unexpectedly shows a significantly higher tolerance value, especially transfection complex 5 shows a maximum tolerated dose value of about 1.4-2.9 times that of the control transfection complex 2. On the other hand, within the dose range of 10.8-15.2 mg / kg body weight, the control transfection complex has shown a high proportion of hepatotoxic reactions, while at the same dose, the experimental animals given the transfection complex of the present invention unexpectedly showed lower toxic reactions in liver autopsy, especially the experimental animals given transfection complex 5 in the same dose range did not show any obvious abnormalities in liver autopsy.

[0307] According to the results of the above examples, it can be found that the amine-containing transfection reagent disclosed in the present invention has a delivery efficiency that is close to or even better than that of the prior art compounds, and unexpectedly shows significantly lower acute toxicity. Therefore, it has broad and effective application prospects in the delivery of bioactive agents, especially the delivery of functional oligonucleotides.

[0308] The specific implementation modes of the present disclosure are described in detail above. However, the present disclosure is not limited to the specific details in the above implementation modes. Within the technical concept of the present disclosure, a variety of simple modifications can be made to the technical solutions of the present disclosure, and these simple modifications all belong to the protection scope of the present disclosure.

[0309] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present disclosure will not further describe various possible combinations.

[0310] In addition, various embodiments of the present disclosure may be arbitrarily combined, and as long as such combination does not violate the concept of the present disclosure, it should also be regarded as the content disclosed by the present disclosure.

Claims

1. An amine-containing transfection reagent, which is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, in, Y1 is selected from a C3-C5 straight chain alkylene group; Each Y2 is a C2-C3 alkylene group having a hydroxyl substituent; Each R1 is the same or different and is independently selected from H or a group represented by formula (Ii); each R2 is independently a group represented by formula (I-ii), Among them, each R a Independently selected from C10-C18 straight chain alkyl; each R b are independently C8-C16 straight chain alkyl groups, each R c All are hydroxyl groups, Indicates the site to which a group is covalently attached.

2. The amine-containing transfection reagent according to claim 1, wherein Both R1 are H; or, one R1 is H and the other R1 is a group represented by (Ii).

3. The amine-containing transfection reagent according to claim 1, wherein The amine-containing transfection reagent is selected from one or more of the compounds represented by the structures of formula (101) to (103) and pharmaceutically acceptable salts thereof:

4. A transfection complex comprising a key lipid, wherein the key lipid is the amine-containing transfection reagent according to any one of claims 1 to 3.

5. The transfection complex according to claim 4, wherein The transfection complex further comprises a helper lipid and / or a PEGylated lipid.

6. The transfection complex according to claim 5, wherein The molar ratio between the key lipid, the auxiliary lipid and the PEGylated lipid is (19.7-80):(19.7-80):(0.3-50).

7. The transfection complex according to claim 6, wherein The molar ratio between the key lipid, the auxiliary lipid and the PEGylated lipid is (50-70):(20-40):(3-30).

8. The transfection complex according to any one of claims 4 to 7, wherein The transfection complex also includes a biologically active agent.

9. The transfection complex according to claim 8, wherein The weight ratio of the bioactive agent to the total lipids contained in the transfection complex is 1:1-1:200, and the total lipids refer to the sum of key lipids, auxiliary lipids and PEGylated lipids.

10. The transfection complex according to claim 9, wherein The weight ratio is 1:1-1:

50.

11. The transfection complex according to claim 10, wherein The weight ratio is 1:3-1:

17.

12. The transfection complex according to claim 8, wherein The bioactive agent is selected from functional oligonucleotides or pharmaceutically acceptable salts thereof.

13. The transfection complex according to claim 12, wherein The functional oligonucleotide is siRNA or a pharmaceutically acceptable salt thereof.

14. Use of the transfection complex described in any one of claims 4 to 13 in the preparation of a drug for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in a cell, wherein the specific gene is selected from the group consisting of a hepatitis B virus gene, angiopoietin-like protein 3 gene or apolipoprotein C3 gene.

15. A kit comprising the transfection complex according to any one of claims 4 to 13.